false --12-31 Q1 0001622244 0001622244 2024-01-01 2024-03-31 0001622244 2024-06-10 0001622244 2024-03-31 0001622244 2023-12-31 0001622244 us-gaap:RelatedPartyMember 2024-03-31 0001622244 us-gaap:RelatedPartyMember 2023-12-31 0001622244 us-gaap:NonrelatedPartyMember 2024-03-31 0001622244 us-gaap:NonrelatedPartyMember 2023-12-31 0001622244 OWPC:SeriesAConvertiblePreferredStockMember 2024-03-31 0001622244 OWPC:SeriesAConvertiblePreferredStockMember 2023-12-31 0001622244 OWPC:SeriesBConvertiblePreferredStockMember 2024-03-31 0001622244 OWPC:SeriesBConvertiblePreferredStockMember 2023-12-31 0001622244 2023-01-01 2023-03-31 0001622244 us-gaap:PreferredStockMember OWPC:SeriesAConvertiblePreferredStockMember 2023-12-31 0001622244 us-gaap:PreferredStockMember OWPC:SeriesBConvertiblePreferredStockMember 2023-12-31 0001622244 us-gaap:CommonStockMember 2023-12-31 0001622244 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001622244 OWPC:SubscriptionsPayableMember 2023-12-31 0001622244 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001622244 us-gaap:RetainedEarningsMember 2023-12-31 0001622244 us-gaap:PreferredStockMember OWPC:SeriesAConvertiblePreferredStockMember 2022-12-31 0001622244 us-gaap:PreferredStockMember OWPC:SeriesBConvertiblePreferredStockMember 2022-12-31 0001622244 us-gaap:CommonStockMember 2022-12-31 0001622244 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001622244 OWPC:SubscriptionsPayableMember 2022-12-31 0001622244 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001622244 us-gaap:RetainedEarningsMember 2022-12-31 0001622244 2022-12-31 0001622244 us-gaap:PreferredStockMember OWPC:SeriesAConvertiblePreferredStockMember 2024-01-01 2024-03-31 0001622244 us-gaap:PreferredStockMember OWPC:SeriesBConvertiblePreferredStockMember 2024-01-01 2024-03-31 0001622244 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001622244 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001622244 OWPC:SubscriptionsPayableMember 2024-01-01 2024-03-31 0001622244 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001622244 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001622244 us-gaap:PreferredStockMember OWPC:SeriesAConvertiblePreferredStockMember 2023-01-01 2023-03-31 0001622244 us-gaap:PreferredStockMember OWPC:SeriesBConvertiblePreferredStockMember 2023-01-01 2023-03-31 0001622244 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001622244 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001622244 OWPC:SubscriptionsPayableMember 2023-01-01 2023-03-31 0001622244 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001622244 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001622244 us-gaap:PreferredStockMember OWPC:SeriesAConvertiblePreferredStockMember 2024-03-31 0001622244 us-gaap:PreferredStockMember OWPC:SeriesBConvertiblePreferredStockMember 2024-03-31 0001622244 us-gaap:CommonStockMember 2024-03-31 0001622244 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001622244 OWPC:SubscriptionsPayableMember 2024-03-31 0001622244 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001622244 us-gaap:RetainedEarningsMember 2024-03-31 0001622244 us-gaap:PreferredStockMember OWPC:SeriesAConvertiblePreferredStockMember 2023-03-31 0001622244 us-gaap:PreferredStockMember OWPC:SeriesBConvertiblePreferredStockMember 2023-03-31 0001622244 us-gaap:CommonStockMember 2023-03-31 0001622244 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001622244 OWPC:SubscriptionsPayableMember 2023-03-31 0001622244 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001622244 us-gaap:RetainedEarningsMember 2023-03-31 0001622244 2023-03-31 0001622244 OWPC:MergerAgreementMember OWPC:OWPVenturesIncMember 2019-02-20 2019-02-21 0001622244 OWPC:MergerAgreementMember OWPC:OWPVenturesIncMember 2019-02-21 0001622244 OWPC:MergerAgreementMember 2019-02-20 2019-02-21 0001622244 OWPC:MergerAgreementMember 2019-02-21 0001622244 OWPC:MergerAgreementMember OWPC:OWPVenturesIncMember 2022-01-01 2022-03-31 0001622244 2023-01-01 2023-12-31 0001622244 OWPC:OneWorldProductsIncMember 2024-01-01 2024-03-31 0001622244 OWPC:OWPVenturesIncMember 2024-01-01 2024-03-31 0001622244 2023-12-22 2023-12-22 0001622244 srt:SubsidiariesMember 2024-03-31 0001622244 srt:SubsidiariesMember 2023-12-31 0001622244 srt:SubsidiariesMember 2024-01-01 2024-03-31 0001622244 2024-03-15 0001622244 2023-06-15 2023-06-15 0001622244 OWPC:OfficersAndDirectorsMember us-gaap:CommonStockMember 2024-05-15 2024-05-15 0001622244 OWPC:IsiahThomasIIIMember us-gaap:CommonStockMember 2024-03-15 2024-03-15 0001622244 OWPC:IsiahThomasIIIMember us-gaap:CommonStockMember 2024-03-15 0001622244 OWPC:DrKennethPeregoIIMember us-gaap:CommonStockMember 2024-03-15 2024-03-15 0001622244 OWPC:DrKennethPeregoIIMember us-gaap:CommonStockMember 2024-03-15 0001622244 OWPC:TerryBuffaloIMember us-gaap:CommonStockMember 2024-03-15 2024-03-15 0001622244 OWPC:TerryBuffaloIMember us-gaap:CommonStockMember 2024-03-15 0001622244 OWPC:MrJoergSommerMember us-gaap:CommonStockMember 2024-03-15 2024-03-15 0001622244 OWPC:MrJoergSommerMember us-gaap:CommonStockMember 2024-03-15 0001622244 us-gaap:CommonStockMember 2024-03-15 2024-03-15 0001622244 us-gaap:CommonStockMember 2024-03-15 0001622244 OWPC:IsiahThomasIIIMember 2024-03-15 2024-03-15 0001622244 OWPC:IsiahThomasIIIMember 2024-03-15 0001622244 OWPC:DrKennethPeregoIIMember 2024-03-15 2024-03-15 0001622244 OWPC:DrKennethPeregoIIMember 2024-03-15 0001622244 OWPC:MrJoergSommerMember 2024-03-15 2024-03-15 0001622244 OWPC:MrJoergSommerMember 2024-03-15 0001622244 OWPC:DrJohnMcCabeMember 2024-03-15 2024-03-15 0001622244 OWPC:DrJohnMcCabeMember 2024-03-15 0001622244 2024-03-15 2024-03-15 0001622244 us-gaap:FairValueInputsLevel1Member 2024-03-31 0001622244 us-gaap:FairValueInputsLevel2Member 2024-03-31 0001622244 us-gaap:FairValueInputsLevel3Member 2024-03-31 0001622244 us-gaap:FairValueInputsLevel1Member 2023-12-31 0001622244 us-gaap:FairValueInputsLevel2Member 2023-12-31 0001622244 us-gaap:FairValueInputsLevel3Member 2023-12-31 0001622244 us-gaap:ConvertibleDebtMember OWPC:PromissoryNoteMember us-gaap:RelatedPartyMember 2024-03-31 0001622244 us-gaap:ConvertibleDebtMember OWPC:PromissoryNoteMember us-gaap:RelatedPartyMember 2023-12-31 0001622244 us-gaap:ConvertibleDebtMember us-gaap:RelatedPartyMember 2024-03-31 0001622244 us-gaap:ConvertibleDebtMember us-gaap:RelatedPartyMember 2023-12-31 0001622244 OWPC:PromissoryNoteMember OWPC:JohnMcCabeInvestmentsLLCMember 2022-09-27 0001622244 OWPC:PromissoryNoteMember OWPC:JohnMcCabeInvestmentsLLCMember 2022-09-27 2022-09-27 0001622244 OWPC:PromissoryNoteMember OWPC:JohnMcCabeInvestmentsLLCMember OWPC:SeriesBCommonStockMember 2022-09-27 0001622244 OWPC:PromissoryNoteMember OWPC:JohnMcCabeInvestmentsLLCMember 2024-03-15 0001622244 OWPC:PromissoryNoteMember OWPC:JohnMcCabeInvestmentsLLCMember 2024-03-15 2024-03-15 0001622244 us-gaap:ConvertibleDebtMember us-gaap:RelatedPartyMember 2024-01-01 2024-03-31 0001622244 us-gaap:ConvertibleDebtMember us-gaap:RelatedPartyMember 2023-01-01 2023-03-31 0001622244 OWPC:UnsecuredPromissoryNoteOneMember us-gaap:RelatedPartyMember 2024-03-31 0001622244 OWPC:UnsecuredPromissoryNoteOneMember us-gaap:RelatedPartyMember 2023-12-31 0001622244 OWPC:UnsecuredPromissoryNoteTwoMember us-gaap:RelatedPartyMember 2024-03-31 0001622244 OWPC:UnsecuredPromissoryNoteTwoMember us-gaap:RelatedPartyMember 2023-12-31 0001622244 OWPC:UnsecuredPromissoryNoteThreeMember us-gaap:RelatedPartyMember 2024-03-31 0001622244 OWPC:UnsecuredPromissoryNoteThreeMember us-gaap:RelatedPartyMember 2023-12-31 0001622244 OWPC:UnsecuredPromissoryNoteFourMember us-gaap:RelatedPartyMember 2024-03-31 0001622244 OWPC:UnsecuredPromissoryNoteFourMember us-gaap:RelatedPartyMember 2023-12-31 0001622244 OWPC:UnsecuredPromissoryNoteFiveMember us-gaap:RelatedPartyMember 2024-03-31 0001622244 OWPC:UnsecuredPromissoryNoteFiveMember us-gaap:RelatedPartyMember 2023-12-31 0001622244 OWPC:UnsecuredPromissoryNoteSixMember us-gaap:RelatedPartyMember 2024-03-31 0001622244 OWPC:UnsecuredPromissoryNoteSixMember us-gaap:RelatedPartyMember 2023-12-31 0001622244 OWPC:UnsecuredPromissoryNoteSevenMember us-gaap:RelatedPartyMember 2024-03-31 0001622244 OWPC:UnsecuredPromissoryNoteSevenMember us-gaap:RelatedPartyMember 2023-12-31 0001622244 OWPC:UnsecuredPromissoryNoteEightMember us-gaap:RelatedPartyMember 2024-03-31 0001622244 OWPC:UnsecuredPromissoryNoteEightMember us-gaap:RelatedPartyMember 2023-12-31 0001622244 OWPC:UnsecuredPromissoryNoteNineMember us-gaap:RelatedPartyMember 2024-03-31 0001622244 OWPC:UnsecuredPromissoryNoteNineMember us-gaap:RelatedPartyMember 2023-12-31 0001622244 OWPC:UnsecuredPromissoryNoteTenMember us-gaap:RelatedPartyMember 2024-03-31 0001622244 OWPC:UnsecuredPromissoryNoteTenMember us-gaap:RelatedPartyMember 2023-12-31 0001622244 OWPC:UnsecuredPromissoryNoteElevenMember us-gaap:RelatedPartyMember 2024-03-31 0001622244 OWPC:UnsecuredPromissoryNoteElevenMember us-gaap:RelatedPartyMember 2023-12-31 0001622244 OWPC:UnsecuredPromissoryNoteTwelveMember us-gaap:RelatedPartyMember 2024-03-31 0001622244 OWPC:UnsecuredPromissoryNoteTwelveMember us-gaap:RelatedPartyMember 2023-12-31 0001622244 OWPC:UnsecuredPromissoryNoteThirteenMember us-gaap:RelatedPartyMember 2024-03-31 0001622244 OWPC:UnsecuredPromissoryNoteThirteenMember us-gaap:RelatedPartyMember 2023-12-31 0001622244 OWPC:UnsecuredPromissoryNoteFourteenMember us-gaap:RelatedPartyMember 2024-03-31 0001622244 OWPC:UnsecuredPromissoryNoteFourteenMember us-gaap:RelatedPartyMember 2023-12-31 0001622244 OWPC:UnsecuredPromissoryNoteFifteenMember us-gaap:RelatedPartyMember 2024-03-31 0001622244 OWPC:UnsecuredPromissoryNoteFifteenMember us-gaap:RelatedPartyMember 2023-12-31 0001622244 OWPC:UnsecuredPromissoryNoteSixteenMember us-gaap:RelatedPartyMember 2024-03-31 0001622244 OWPC:UnsecuredPromissoryNoteSixteenMember us-gaap:RelatedPartyMember 2023-12-31 0001622244 OWPC:UnsecuredPromissoryNoteSeventeenMember us-gaap:RelatedPartyMember 2024-03-31 0001622244 OWPC:UnsecuredPromissoryNoteSeventeenMember us-gaap:RelatedPartyMember 2023-12-31 0001622244 OWPC:UnsecuredPromissoryNoteEighteenMember us-gaap:RelatedPartyMember 2024-03-31 0001622244 OWPC:UnsecuredPromissoryNoteEighteenMember us-gaap:RelatedPartyMember 2023-12-31 0001622244 OWPC:UnsecuredPromissoryNoteNineteenMember us-gaap:RelatedPartyMember 2024-03-31 0001622244 OWPC:UnsecuredPromissoryNoteNineteenMember us-gaap:RelatedPartyMember 2023-12-31 0001622244 OWPC:UnsecuredPromissoryNoteTwentyMember us-gaap:RelatedPartyMember 2024-03-31 0001622244 OWPC:UnsecuredPromissoryNoteTwentyMember us-gaap:RelatedPartyMember 2023-12-31 0001622244 OWPC:UnsecuredPromissoryNoteTwentyOneMember us-gaap:RelatedPartyMember 2024-03-31 0001622244 OWPC:UnsecuredPromissoryNoteTwentyOneMember us-gaap:RelatedPartyMember 2023-12-31 0001622244 OWPC:UnsecuredPromissoryNoteTwentyTwoMember us-gaap:RelatedPartyMember 2024-03-31 0001622244 OWPC:UnsecuredPromissoryNoteTwentyTwoMember us-gaap:RelatedPartyMember 2023-12-31 0001622244 OWPC:UnsecuredPromissoryNoteTwentyThreeMember us-gaap:RelatedPartyMember 2024-03-31 0001622244 OWPC:UnsecuredPromissoryNoteTwentyThreeMember us-gaap:RelatedPartyMember 2023-12-31 0001622244 OWPC:UnsecuredPromissoryNoteTwentyFourMember us-gaap:RelatedPartyMember 2024-03-31 0001622244 OWPC:UnsecuredPromissoryNoteTwentyFourMember us-gaap:RelatedPartyMember 2023-12-31 0001622244 OWPC:UnsecuredPromissoryNoteTwentyFiveMember us-gaap:RelatedPartyMember 2024-03-31 0001622244 OWPC:UnsecuredPromissoryNoteTwentyFiveMember us-gaap:RelatedPartyMember 2023-12-31 0001622244 OWPC:UnsecuredPromissoryNoteTwentySixMember us-gaap:RelatedPartyMember 2024-03-31 0001622244 OWPC:UnsecuredPromissoryNoteTwentySixMember us-gaap:RelatedPartyMember 2023-12-31 0001622244 OWPC:UnsecuredPromissoryNotesMember us-gaap:RelatedPartyMember 2024-03-31 0001622244 OWPC:UnsecuredPromissoryNotesMember us-gaap:RelatedPartyMember 2023-12-31 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:JoergSommerMember 2024-03-19 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:JoergSommerMember 2024-03-19 2024-03-19 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:JoergSommerMember 2024-03-15 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:JoergSommerMember 2024-03-15 2024-03-15 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:JoergSommerMember 2024-03-15 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:JoergSommerMember 2024-03-15 2024-03-15 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:JohnMcCabeInvestmentsLLCMember 2024-03-15 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:JohnMcCabeInvestmentsLLCMember 2024-03-15 2024-03-15 0001622244 OWPC:UnsecuredPromissoryNoteOneMember OWPC:JohnMcCabeInvestmentsLLCMember 2024-03-15 0001622244 OWPC:UnsecuredPromissoryNoteOneMember OWPC:JohnMcCabeInvestmentsLLCMember 2024-03-15 0001622244 OWPC:UnsecuredPromissoryNoteOneMember OWPC:JohnMcCabeInvestmentsLLCMember 2024-03-15 2024-03-15 0001622244 OWPC:UnsecuredPromissoryNoteTwoMember OWPC:JohnMcCabeInvestmentsLLCMember 2024-03-15 0001622244 OWPC:UnsecuredPromissoryNoteTwoMember OWPC:JohnMcCabeInvestmentsLLCMember 2024-03-15 0001622244 OWPC:UnsecuredPromissoryNoteTwoMember OWPC:JohnMcCabeInvestmentsLLCMember 2024-03-15 2024-03-15 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:DrKennethPeregoIIMember 2024-03-15 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:DrKennethPeregoIIMember 2024-03-15 2024-03-15 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:DrKennethPeregoIIMember 2024-03-15 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:IsiahThomasIIIMember 2024-03-15 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:IsiahThomasIIIMember 2024-03-15 2024-03-15 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:IsiahThomasIIIMember 2024-03-15 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:IsiahThomasIIIMember 2024-03-15 2024-03-15 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:DrKennethPeregoIIMember 2024-03-12 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:JohnMcCabeInvestmentsLLCMember 2024-03-01 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:JohnMcCabeInvestmentsLLCMember 2024-03-01 2024-03-01 0001622244 OWPC:UnsecuredPromissoryNoteTwoMember OWPC:JohnMcCabeInvestmentsLLCMember 2024-03-15 2024-03-15 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:DrKennethPeregoIIMember 2024-02-26 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:JohnMcCabeInvestmentsLLCMember 2024-01-29 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:JohnMcCabeInvestmentsLLCMember 2024-01-29 2024-01-29 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:DrKennethPeregoIIMember 2024-01-11 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:DrKennethPeregoIIMember 2024-01-08 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:DrKennethPeregoIIMember 2023-11-28 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:JoergSommerMember 2023-10-11 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:JoergSommerMember 2023-10-11 2023-10-11 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:DrKennethPeregoIIMember 2023-09-11 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:DrKennethPeregoIIMember 2023-09-11 2023-09-11 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:DrKennethPeregoIIMember 2023-08-31 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:DrKennethPeregoIIMember 2023-08-31 2023-08-31 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:DrKennethPeregoIIMember 2023-08-14 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:DrKennethPeregoIIMember 2023-08-14 2023-08-14 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:DrKennethPeregoIIMember 2022-08-05 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:DrKennethPeregoIIMember 2022-08-05 2022-08-05 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:IsiahThomasIIIMember 2022-08-02 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:IsiahThomasIIIMember 2022-08-02 2022-08-02 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:JohnMcCabeInvestmentsLLCMember 2022-06-13 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:JohnMcCabeInvestmentsLLCMember 2022-06-13 2022-06-13 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:DrKennethPeregoIIMember 2022-07-07 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:DrKennethPeregoIIMember 2022-07-07 2022-07-07 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:IsiahThomasIIIMember 2022-06-03 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:IsiahThomasIIIMember 2022-06-03 2022-06-03 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:IsiahThomasIIIMember 2022-05-05 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:IsiahThomasIIIMember 2022-05-05 2022-05-05 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:DrKennethPeregoIIMember 2022-05-05 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:DrKennethPeregoIIMember 2022-05-05 2022-05-05 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:JohnMcCabeInvestmentsLLCMember 2022-03-01 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:JohnMcCabeInvestmentsLLCMember 2022-03-01 2022-03-01 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:JohnMcCabeInvestmentsLLCMember 2022-02-15 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:JohnMcCabeInvestmentsLLCMember 2022-02-15 2022-02-15 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:DrKennethPeregoIIMember 2021-12-29 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:DrKennethPeregoIIMember 2021-12-29 2021-12-29 0001622244 us-gaap:RelatedPartyMember 2024-01-01 2024-03-31 0001622244 us-gaap:RelatedPartyMember 2023-01-01 2023-03-31 0001622244 OWPC:UnsecuredPromissoryNoteOneMember 2024-03-31 0001622244 OWPC:UnsecuredPromissoryNoteOneMember 2023-12-31 0001622244 OWPC:UnsecuredPromissoryNoteTwoMember 2024-03-31 0001622244 OWPC:UnsecuredPromissoryNoteTwoMember 2023-12-31 0001622244 OWPC:UnsecuredPromissoryNoteThreeMember 2024-03-31 0001622244 OWPC:UnsecuredPromissoryNoteThreeMember 2023-12-31 0001622244 OWPC:UnsecuredPromissoryNoteOneMember OWPC:SangnineGroupLlcMember OWPC:PurchaseAgreementMember 2024-03-04 0001622244 OWPC:UnsecuredPromissoryNoteOneMember OWPC:SangnineGroupLlcMember OWPC:PurchaseAgreementMember 2024-03-04 2024-03-04 0001622244 OWPC:UnsecuredPromissoryNoteOneMember OWPC:AJBCapitalInvestmentsLLCMember OWPC:PurchaseAgreementMember 2024-03-04 0001622244 OWPC:UnsecuredPromissoryNoteTwoMember OWPC:LDL8ConsultingLLCMember 2023-08-18 0001622244 OWPC:UnsecuredPromissoryNoteThreeMember OWPC:AJBCapitalInvestmentsLLCMember OWPC:PurchaseAgreementMember 2023-06-23 0001622244 OWPC:UnsecuredPromissoryNoteThreeMember OWPC:AJBCapitalInvestmentsLLCMember OWPC:PurchaseAgreementMember 2023-06-23 2023-06-23 0001622244 OWPC:UnsecuredPromissoryNoteThreeMember OWPC:AJBCapitalInvestmentsLLCMember 2023-06-23 2023-06-23 0001622244 OWPC:UnsecuredPromissoryNoteThreeMember OWPC:AJBCapitalInvestmentsLLCMember 2023-06-23 0001622244 OWPC:NotespayableMember 2024-01-01 2024-03-31 0001622244 OWPC:NotespayableMember 2023-01-01 2023-03-31 0001622244 OWPC:SeriesAConvertiblePreferredStockMember 2024-01-01 2024-03-31 0001622244 us-gaap:SeriesAPreferredStockMember 2024-03-31 0001622244 us-gaap:SeriesBPreferredStockMember 2024-03-31 0001622244 us-gaap:SeriesAPreferredStockMember 2024-01-01 2024-03-31 0001622244 OWPC:TysadcoPartnersLLCMember OWPC:ELOCPurchaseAgreementMember 2022-09-01 2022-09-01 0001622244 OWPC:TysadcoPartnersLLCMember OWPC:ELOCPurchaseAgreementMember us-gaap:CommonStockMember 2022-09-01 2022-09-01 0001622244 OWPC:AdvisorAgreementMember 2023-08-22 2023-08-22 0001622244 srt:PresidentMember 2023-05-22 2023-05-22 0001622244 srt:PresidentMember 2023-05-23 2023-05-23 0001622244 OWPC:ScenarioOneMember 2023-05-23 2023-05-23 0001622244 OWPC:ScenarioTwoMember 2023-05-23 2023-05-23 0001622244 OWPC:ScenarioThreeMember 2023-05-23 2023-05-23 0001622244 OWPC:ScenarioFourMember 2023-05-23 2023-05-23 0001622244 us-gaap:CommonStockMember 2024-03-04 2024-03-04 0001622244 OWPC:PromissoryNoteMember OWPC:MrJoergSommerMember 2024-03-19 2024-03-19 0001622244 OWPC:PromissoryNoteMember OWPC:SanguineGroupLlcMember 2024-03-19 2024-03-19 0001622244 OWPC:MrJoergSommerMember us-gaap:CommonStockMember 2023-06-15 2023-06-15 0001622244 us-gaap:CommonStockMember OWPC:OfficersAndDirectorsMember 2024-03-15 2024-03-15 0001622244 OWPC:TwoConsultantsMember us-gaap:CommonStockMember 2024-03-15 2024-03-15 0001622244 OWPC:ClearThinkCapitalPartnersLLCMember us-gaap:CommonStockMember 2024-02-09 2024-02-09 0001622244 OWPC:ClearThinkCapitalPartnersLLCMember us-gaap:CommonStockMember 2024-03-31 2024-03-31 0001622244 OWPC:BoardOfDirectorsMember OWPC:TwoThousandNineteenStockIncentivePlanMember 2020-02-11 2020-02-12 0001622244 OWPC:TwoThousandNineteenStockIncentivePlanMember 2024-01-01 2024-03-31 0001622244 OWPC:OfficersDirectorsAndEmployeesMember 2024-03-31 0001622244 us-gaap:SubsequentEventMember OWPC:SDTEquitiesLLCMember 2024-04-19 2024-04-19 0001622244 us-gaap:SubsequentEventMember OWPC:SDTEquitiesLLCMember 2024-04-19 0001622244 us-gaap:SubsequentEventMember OWPC:AJBCapitalInvestmentsLLCMember 2024-04-19 0001622244 us-gaap:SubsequentEventMember OWPC:AJBCapitalInvestmentsLLCMember 2024-04-19 2024-04-19 0001622244 us-gaap:SubsequentEventMember 2024-04-19 2024-04-19 0001622244 us-gaap:SubsequentEventMember 2024-04-19 0001622244 us-gaap:SubsequentEventMember OWPC:PreFundedWarrantMember 2024-04-19 0001622244 us-gaap:SubsequentEventMember OWPC:PreFundedWarrantMember 2024-04-19 2024-04-19 0001622244 us-gaap:SubsequentEventMember OWPC:AJBCapitalInvestmentsLLCMember OWPC:DrKennethPeregoIIMember 2024-04-19 0001622244 us-gaap:SubsequentEventMember OWPC:AJBCapitalInvestmentsLLCMember OWPC:DrKennethPeregoIIMember 2024-04-19 2024-04-19 0001622244 OWPC:PromissoryNoteMember OWPC:AJBCapitalInvestmentsLLCMember us-gaap:SubsequentEventMember 2024-04-19 2024-04-19 0001622244 us-gaap:SubsequentEventMember 2024-05-10 2024-05-10 0001622244 OWPC:ClearThinkCapitalPartnersLLCMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2024-05-10 2024-05-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares utr:sqft OWPC:Integer iso4217:COP xbrli:pure

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
    SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2024

 

OR

 

  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
    SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ____________ to ____________

 

Commission file number: 000-56151

 

 

ONE WORLD PRODUCTS, INC.

(Exact name of registrant as specified in its charter)

 

Nevada   61-1744826

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

     

6605 Grand Montecito Pkwy, Suite 100,

Las Vegas, Nevada 89149

  89149
(Address of principal executive offices)   (zip code)

 

(800) 605-3210

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
N/A   N/A   N/A

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

 

Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

 

Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer Accelerated filer
Non-accelerated filer Smaller reporting company
    Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

 

Yes ☐ No

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock as of the latest practicable date.

 

The number of shares of registrant’s common stock outstanding as of June 10, 2024 was 104,329,919.

 

 

 

 

 

 

TABLE OF CONTENTS

 

    Page
PART I - FINANCIAL INFORMATION   1
ITEM 1. FINANCIAL STATEMENTS (Unaudited)   1
  Condensed Consolidated Balance Sheets as of March 31, 2024 (Unaudited) and December 31, 2023   1
  Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three Months Ended March 31, 2024 and 2023 (Unaudited)   2
  Consolidated Statements of Changes in Stockholders’ Equity (Deficit) for the Three Months Ended March 31, 2024 and 2023 (Unaudited)   3
  Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2024 and 2023 (Unaudited)   5
  Notes to the Condensed Consolidated Financial Statements (Unaudited)   6
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS   21
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK   24
ITEM 4. CONTROLS AND PROCEDURES   25
PART II - OTHER INFORMATION   26
ITEM 1. Legal Proceedings   26
ITEM 1A. RISK FACTORS   26
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS   26
ITEM 3. DEFAULTS UPON SENIOR SECURITIES   27
ITEM 4. MINE SAFETY DISCLOSURES   27
ITEM 5. OTHER INFORMATION   27
ITEM 6. EXHIBITS   28
  SIGNATURES   29

 

 

 

 

PART I – FINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS

 

ONE WORLD PRODUCTS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

 

   March 31,   December 31, 
   2024   2023 
   (Unaudited)      
           
Assets          
Current assets:          
Cash  $40,648   $726 
Accounts receivable   282    - 
Inventory   26,257    - 
Prepaid expenses   31,654    13,156 
Total current assets   98,841    13,882 
           
Security deposits   85,000    85,000 
           
Total Assets  $183,841   $98,882 
           
Liabilities and Stockholders’ Equity (Deficit)          
           
Current liabilities:          
Accounts payable  $618,956   $528,645 
Accrued expenses   871,836    939,368 
Dividends payable   211,650    196,734 
Convertible note payable, related party, current maturities   -    750,000 
Notes payable, related parties, current maturities   -    1,146,500 
Notes payable, net of $126,670 and $24,136 of debt discounts at March 31, 2024 and December 31, 2023, respectively   268,330    310,864 
Total current liabilities   1,970,772    3,872,111 
           
Notes payable, related parties, long-term portion, net of $9,729 of debt discounts at March 31, 2024   2,441,252    - 
           
Total Liabilities   4,412,024    3,872,111 
          
Series A convertible preferred stock, $0.001 par value, 500,000 shares authorized; 99,733 and 70,233 shares issued and outstanding at December 31, 2023 and 2022, respectively   997,330    997,330 
Series B convertible preferred stock, $0.001 par value, 600,000 shares authorized; 238,501 and 272,168 shares issued and outstanding at December 31, 2023 and 2022, respectively   3,577,515    3,577,515 
           
Stockholders’ Equity (Deficit):          
Preferred stock, $0.001 par value, 9,200,000 shares authorized; no shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively   -    - 
Common stock, $0.001 par value, 300,000,000 shares authorized; 111,092,849 and 79,827,618 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively   111,093    79,828 
Additional paid-in capital   19,646,892    18,414,456 
Subscriptions payable   69,695    45,000 
Accumulated other comprehensive income   -    42,328 
Accumulated (deficit)   (28,630,708)   (26,929,686)
Total Stockholders’ Equity (Deficit)   (8,803,028)   (8,348,074)
           
Total Liabilities and Stockholders’ Equity (Deficit)  $183,841   $98,882 

 

See accompanying notes to condensed consolidated financial statements.

 

1

 

 

ONE WORLD PRODUCTS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Unaudited)

 

   2024   2023 
   For the Three Months Ended 
   March 31, 
   2024   2023 
         
Revenues  $282   $2,101 
Cost of goods sold   49    967 
Gross loss   233    1,134 
           
Operating expenses:          
General and administrative   198,847    347,297 
Professional fees   578,671    103,848 
Depreciation expense   -    7,857 
Total operating expenses   777,518    459,002 
           
Operating loss   (777,285)   (457,868)
           
Other income (expense):          
Loss on early extinguishment of debt   (724,086)   - 
Loss on deconsolidation of foreign subsidiaries   (97,672)   - 
Interest expense   (101,979)   (58,070)
Total other expense   (923,737)   (58,070)
           
Net loss  $(1,701,022)  $(515,938)
           
Other comprehensive loss:          
Gain (loss) on foreign currency translation  $(42,328)  $184,969 
           
Net other comprehensive loss  $(1,743,350)  $(330,969)
Series A convertible preferred stock declared ($0.60 per share)   (14,916)   (12,773)
Net loss attributable to common shareholders  $(1,758,266)  $(343,742)
          
Weighted average number of common shares outstanding - basic and diluted   86,930,048    68,702,907 
           
Net loss per share - basic and diluted  $(0.02)  $(0.01)
           
Dividends declared per share of common stock  $0.00   $0.00 

 

See accompanying notes to condensed consolidated financial statements.

 

2

 

 

ONE WORLD PRODUCTS, INC.

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT)

(Unaudited)

 

   Shares   Amount   Shares   Amount   Shares   Amount   Capital   Payable   (Loss)   Deficit   (Deficit) 
   For the Three Months Ended March 31, 2024 
   Series A Convertible   Series B Convertible          Additional       Accumulated
Other
Comprehensive
      

Total

Stockholders’

 
   Preferred Stock  Preferred Stock   Common Stock   Paid-In   Subscriptions   Income   Accumulated   Equity 
   Shares   Amount   Shares   Amount   Shares   Amount   Capital   Payable   (Loss)   Deficit   (Deficit) 
                                             
Balance, December 31, 2023   99,733   $997,330    238,501   $3,577,515    79,827,618   $79,828   $18,414,456   $45,000   $42,328   $(26,929,686)  $      (8,348,074)
                                                        
Common Stock issued for services   -    -    -    -    7,149,621    7,150    460,236    24,695    -    -    492,081 
                                                        
Common Stock issued for debt commitment fees   -    -    -    -    2,750,000    2,750    80,543    -    -    -    83,293 
                                                        
Common stock issued to debt holder in escrow, to be cancelled   -    -    -    -    10,394,610    10,394    (10,394)   -    -    -    - 
                                                        
Common stock issued pursuant to debt modifications   -    -    -    -    10,971,000    10,971    713,115    -    -    -    724,086 
                                                        
Amortization of common stock options issued for services   -    -    -    -    -    -    3,852    -    -    -    3,852 
                                                        
Series A convertible preferred stock dividend declared ($0.60 per share)   -    -    -    -    -    -    (14,916)   -    -    -    (14,916)
                                                        
Loss on foreign currency translation   -    -    -    -    -    -    -    -    (42,328)   -    (42,328)
                                                        
Net loss   -    -    -    -    -    -    -    -    -    (1,701,022)   (1,701,022)
                                                        
Balance, March 31, 2024   99,733   $997,330    238,501   $3,577,515    111,092,849   $111,093   $19,646,892   $69,695   $-   $(28,630,708)  $(8,803,028)

 

3

 

 

   For the Three Months Ended March 31, 2023 
   Series A Convertible   Series B Convertible           Additional       Accumulated
Other
       Total
Stockholders’
 
   Preferred Stock   Preferred Stock   Common Stock   Paid-In   Subscriptions   Comprehensive   Accumulated   Equity 
   Shares   Amount   Shares   Amount   Shares   Amount   Capital   Payable   Income (Loss)   Deficit   (Deficit) 
                                             
Balance, December 31, 2022   70,233   $702,330    272,168   $4,082,520    67,202,907   $67,203   $17,123,603   $               -   $(50,699)  $(22,976,365)  $      (5,836,258)
                                                        
Series A Convertible Preferred Stock sold for cash   15,000    150,000    -    -    -    -    -    -    -    -    - 
                                                        
Series A Convertible Preferred Stock issued for services   4,500    45,000    -    -    -    -    -    -    -    -    - 
                                                        
Common stock sold for cash   -    -    -    -    3,000,000    3,000    297,000    -    -    -    300,000 
                                                        
Amortization of common stock options issued for services   -    -    -    -    -    -    38,130    -    -    -    38,130 
                                                        
Series A convertible preferred stock dividend declared ($0.60 per share)   -    -    -    -    -    -    (12,773)   -    -    -    (12,773)
                                                        
Gain on foreign currency translation   -    -    -    -    -    -    -    -    184,969    -    184,969 
                                                        
Net loss   -    -    -    -    -    -    -    -    -    (515,938)   (515,938)
                                                        
Balance, March 31, 2023   89,733   $897,330    272,168   $4,082,520    70,202,907   $70,203   $17,445,960   $-   $134,270   $(23,492,303)  $(5,841,870)

 

See accompanying notes to condensed consolidated financial statements.

 

4

 

 

ONE WORLD PRODUCTS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

 

   2024   2023 
   For the Three Months Ended 
   March 31, 
   2024   2023 
Cash flows from operating activities          
Net loss  $(1,701,022)  $(515,938)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation and amortization expense   -    7,857 
Loss on early extinguishment of debt   724,086    - 
Amortization of debt discounts   46,030    - 
Series A preferred stock issued for services   -    45,000 
Common stock issued for services   492,081    - 
Stock options issued for services   3,852    38,130 
Decrease (increase) in assets:          
Accounts receivable   (282)   1,673 
Inventory   (26,257)   (225,037)
Other current assets   (18,498)   (27,353)
Other assets   -    (7,023)
Right-of-use assets   -    22,242 
Security deposits   -    (16)
Increase (decrease) in liabilities:          
Accounts payable   90,311    (50,344)
Accrued expenses   139,949    171,267 
Deferred revenues   -    (1,694)
Lease liability   -    (20,747)
Net cash used in operating activities   (249,750)   (561,983)
           
Cash flows from investing activities          
Purchase of fixed assets   -    (5,046)
Net cash used in investing activities   -    (5,046)
           
Cash flows from financing activities          
Proceeds from notes payable, related parties   347,000    - 
Proceeds from notes payable   285,000    - 
Repayments of notes payable   (300,000)   - 
Proceeds from sale of preferred and common stock   -    450,000 
Net cash provided by financing activities   332,000    450,000 
           
Effect of exchange rate changes on cash   (42,328)   190,722 
           
Net increase (decrease) in cash   39,922    73,693 
Cash - beginning   726    11,016 
Cash - ending  $40,648   $84,709 
           
Supplemental disclosures:          
Interest paid  $10,500   $22,192 
Income taxes paid  $-   $- 
           
Non-cash investing and financing transactions:          
Dividends payable  $14,916   $12,773 
Value of debt discounts attributable to commitment shares to related parties  $9,839   $- 
Value of debt discounts attributable to commitment shares  $73,454   $- 

 

See accompanying notes to condensed consolidated financial statements.

 

5

 

 

ONE WORLD PRODUCTS, INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

 

Note 1 – Nature of Business and Significant Accounting Policies

 

Nature of Business

 

One World Products, Inc. (the “Company,” “we,” “our” or “us”) was incorporated in Nevada on September 2, 2014. On February 21, 2019, the Company entered into an Agreement and Plan of Merger with OWP Merger Subsidiary, Inc., a wholly-owned subsidiary, and OWP Ventures, Inc. (“OWP Ventures”), which is the parent company of One World Pharma SAS, a Colombian Simplified Shares Company (“OWP SAS”). Pursuant to the Merger Agreement, we acquired OWP Ventures (and indirectly, OWP SAS) by the merger of OWP Merger Subsidiary with and into OWP Ventures, with OWP Ventures being the surviving entity as our wholly-owned subsidiary (the “Merger”). As a result of the Merger (a) holders of the outstanding capital stock of OWP Ventures received an aggregate of 39,475,398 shares of our common stock; (b) options to purchase 825,000 shares of common stock of OWP Ventures at an exercise price of $0.50 automatically converted into options to purchase 825,000 shares of our common stock at an exercise price of $0.50; (c) the outstanding principal and interest under a $300,000 convertible note issued by OWP Ventures became convertible, at the option of the holder, into shares of the Company’s common stock at a conversion price equal to the lesser of $0.424 per share or 80% of the price the Company sold its common stock in a future “Qualified Offering”; (d) 875,000 shares of our common stock owned by OWP Ventures prior to the Merger were cancelled; and (e) OWP Ventures’ chief operating officer became our chief operating officer and two of OWP Ventures’ directors became members of our board of directors. The Company’s headquarters are located in Las Vegas, Nevada, and its customers will predominantly be located outside of the United States. On January 10, 2019, the Company changed its name from Punto Group, Corp. to One World Pharma, Inc., and on November 23, 2021, the Company changed its name to One World Products, Inc. through the merger of One World Products, Inc., a recently formed Nevada corporation wholly-owned by the Company, with and into the Company (the “Name Change Merger”) pursuant to the applicable provisions of the Nevada Revised Statutes (“NRS”). As permitted by the NRS, the articles of merger filed with the Secretary of State of the state of Nevada to effect the Name Change Merger amended Article I of the Company’s Articles of Incorporation to change the Company’s name to “One World Products, Inc.” The Name Change Merger was effected solely to effect the change of the Company’s name, and had no effect on the Company’s officers, directors, operations, assets or liabilities.

 

OWP Ventures is a holding company formed in Delaware on March 27, 2018 to enter and support the cannabis industry, and on May 30, 2018, it acquired OWP SAS. OWP SAS is a licensed cannabis cultivation, production and distribution (export) company located in Popayán, Colombia (nearest major city is Cali). The Company plans to be a producer of and/or source raw and processed cannabis and hemp plant ingredients for both medical and industrial uses across the globe. The Company has received licenses to cultivate, produce and distribute the raw ingredients of the cannabis and hemp plant for medicinal, scientific and industrial purposes. Specifically, the Company is one of the few companies in Colombia to receive all four licenses, including seed use, cultivation of non-psychoactive cannabis, cultivation of psychoactive cannabis, and manufacturing allowing for extraction and export. Currently, we own approximately 30 acres and have a covered greenhouse built specifically to cultivate high-grade cannabis and hemp. In addition, the Company has entered into agreements with local farming cooperatives that include small farmers and indigenous tribe members, under which they will cultivate cannabis on up to approximately 140 acres of land using our seeds and propagation techniques, and sell their harvested products to us on an exclusive basis. The Company began harvesting cannabis in the first quarter of 2019 for the purpose of further research and development activities, quality control testing and extraction. OWP SAS has generated revenue since the second quarter of 2020. During the first quarter of 2022, the Company made payments of approximately $1,400,000 for a state-of-the-art distillation machine that cleared customs and is currently located in a warehouse near Bogotá.

 

On December 22, 2023, OWP SAS, filed for protection under Colombian Law 1116 of 2006, which is the primary legislation governing business insolvency proceedings (restructuring and liquidation) (“Reorganization Proceedings”) in Colombia. The Reorganization Proceeds are similar to Chapter 11 of the United States Bankruptcy Code (the “Bankruptcy Code”) in the United States, whereby the Company intends to restructure its debts and continue to operate.

 

In connection with the Reorganization Proceedings, we paused production and sales of our cannabis operations in Colombia until the court overseeing the Reorganization Proceedings (the “Court”) provides the Company with a plan of reorganization, at which time the Company intends to resume operations and satisfy its obligations in Colombia in accordance with the Court’s plan. Furthermore, we continued our aggressive cost-cutting actions that included significant personnel reductions. As a result of these actions, OWP SAS has no revenue-producing operations. The Company’s primary operations during the fourth quarter of 2023, and to date in 2024, have consisted of activities associated with completing the Reorganization Proceedings, resolving substantial litigation, claims reconciliation, and preparing for emergence from Reorganization Proceedings as contemplated in the yet to be determined, Proposed Plan.

 

Upon the date that the Proposed Plan, which is yet to be determined and remains subject to Court approval, becomes effective (the “Effective Date”), and subject to the effectiveness of the Proposed Plan, it is contemplated that the near term operations of the Company (also referred to as the “Post-Effective Date Debtors”) will consist of (a) claims administration under the Proposed Plan, (b) addressing the litigation, (c) prosecuting, pursuing, compromising, settling, or otherwise disposing of other retained causes of action, (d) defending the Company against any counterclaims, (e) attempting to realize value, if any, from our assets and (f) satisfying other regulatory requirements.

 

6

 

 

ONE WORLD PRODUCTS, INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

 

In the future, the Post-Effective Date Debtors expect to explore potential business opportunities, including strategic partnerships, including those designed to maximize the Debtor’s assets, including restoration of the Company’s cannabis operations. No assurance can be made that the Proposed Plan will become effective or that we will be successful in prosecuting any claim or cause of action or that any strategic alternative will be identified and/or would result in profitable operations.

 

In accordance with ASC 810-10-15, the Company has deconsolidated its foreign subsidiaries until it emerges from the Reorganization Proceedings to include the petitioning entity, OWP SAS, as well as the Company’s non-operating shell entities, Agrobase, S.A.S. and Hope Colombia, S.A.S., given the lack of independently identifiable operations. The deconsolidation resulted in a loss on deconsolidation of foreign subsidiaries in the amount of $97,672 and $1,564,823 for the three months ended March 31, 2024 and the year ended December 31, 2023, respectively.

 

During March of 2024, the Company, through OWP Ventures, began to sell a CBD-based therapeutic product in the United States in limited quantities.

 

Financial Reporting Under Reorganization

 

The Unaudited Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q have been prepared to reflect the application of Financial Accounting Standards Board, or “FASB” Accounting Standards Codification, or “ASC” 852, Reorganizations, which is a critical accounting policy. During the pendency of the bankruptcy protection under Colombian Law 1116 of 2006, the foreign subsidiaries have been deconsolidated, as disclosed in Note 3, below.

 

Effective as of the Petition Date, the Company ceased recognizing interest income on intercompany loans made to the foreign subsidiaries. Subsequent loans advanced to, or payments made on behalf of these foreign subsidiaries, have been recognized as a loss on deconsolidation of foreign subsidiaries.

 

In connection with the Company’s emergence from the bankruptcy protection under Colombian Law 1116 of 2006 on the Effective Date, the Company expects to adopt fresh-start accounting, which will result in the foreign subsidiaries becoming new entities for financial reporting purposes. Upon adoption of fresh-start accounting, the Company’s assets and liabilities will be recorded at their fair value as of the fresh-start reporting date or Effective Date. The fair values of the Company’s assets and liabilities as of that date may differ materially from the recorded values of its assets and liabilities as reflected in its historical consolidated financial statements. In addition, the Company’s adoption of fresh-start accounting may materially affect its results of operations following the fresh-start reporting dates, as the Company will have a new basis in its assets and liabilities. Consequently, the Company’s financial statements on or after the Effective Date will not be comparable with the financial statements prior to that date and the historical financial statements will not be reliable indicators of its financial condition and results of operations for any period after it adopts fresh-start accounting. The Company is in the process of evaluating the potential impact of the fresh-start accounting on its consolidated financial statements.

 

Basis of Presentation

 

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) and the rules of the Securities and Exchange Commission (SEC). Intercompany accounts and transactions have been eliminated.

 

The unaudited condensed consolidated financial statements of the Company and the accompanying notes included in this Quarterly Report on Form 10-Q are unaudited. In the opinion of management, all adjustments necessary for a fair presentation of the Condensed Consolidated Financial Statements have been included. Such adjustments are of a normal, recurring nature. The Condensed Consolidated Financial Statements, and the accompanying notes, are prepared in accordance with GAAP and do not contain certain information included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023. The interim Condensed Consolidated Financial Statements should be read in conjunction with that Annual Report on Form 10-K. Results for the interim periods presented are not necessarily indicative of the results that might be expected for the entire fiscal year.

 

Principles of Consolidation

 

The accompanying consolidated financial statements include the accounts of the following entities, all of which were under common control and ownership at March 31, 2024:

 

    State of    
Name of Entity   Incorporation   Relationship
One World Products, Inc.(1)   Nevada   Parent
OWP Ventures, Inc.(2)   Delaware   Subsidiary

 

(1) Holding company in the form of a corporation.
(2) Holding company in the form of a corporation and wholly-owned subsidiary of One World Products, Inc.

 

The consolidated financial statements herein contain the operations of the wholly-owned subsidiaries listed above. The Company’s headquarters are located in Las Vegas, Nevada.

 

Reclassifications

 

Certain reclassifications have been made to the prior years’ financial statements to conform to current year presentation. These reclassifications had no effect on previously reported results of operations or retained earnings.

 

Foreign Currency Translation

 

The functional currency of the Company is Colombian Peso (COP). The Company has maintained its financial statements using the functional currency, and translated those financial statements to the US Dollar (USD) throughout this report. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency at rates of exchange prevailing at the balance sheet dates. Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Exchange gains or losses arising from foreign currency transactions are included in the determination of net income (loss) for the respective periods.

 

7

 

 

ONE WORLD PRODUCTS, INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

 

Comprehensive Income

 

The Company has adopted the Financial Accounting Standards Boards (“FASB”) Accounting Standards Codification (“ASC”) 220, Reporting Comprehensive Income, which establishes standards for reporting and displaying comprehensive income, its components, and accumulated balances in a full-set of general-purpose financial statements. Accumulated other comprehensive income represents the accumulated balance of foreign currency translation adjustments.

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.

 

Segment Reporting

 

ASC Topic 280, “Segment Reporting,” requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s management organizes segments within the company for making operating decisions and assessing performance. The Company operates as a single segment and will evaluate additional segment disclosure requirements as it expands its operations.

 

Fair Value of Financial Instruments

 

The Company discloses the fair value of certain assets and liabilities in accordance with ASC 820 – Fair Value Measurement and Disclosures (ASC 820). Under ASC 820-10-05, the FASB establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value measurements. This Statement reaffirms that fair value is the relevant measurement attribute. The adoption of this standard did not have a material effect on the Company’s financial statements as reflected herein. The carrying amounts of cash, accounts receivable, accounts payable and accrued expenses reported on the balance sheets are estimated by management to approximate fair value primarily due to the short-term nature of the instruments.

 

Cash in Excess of FDIC Insured Limits

 

The Company maintains its cash in bank deposit accounts which, at times, may exceed federally insured limits. Accounts are guaranteed by the Federal Deposit Insurance Corporation (FDIC) up to $250,000, under current regulations. The Company did not have any cash in excess of FDIC insured limits at March 31, 2024, and has not experienced any losses in such accounts.

 

Revenue Recognition

 

The Company recognizes revenue in accordance with ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. The Company’s revenues in the current period consisted of the sale of our CBD rub, and in the prior period revenues consisted entirely of the sale of seeds. The sale of seeds included multi-element arrangements whereby the Company collected 50% of the sale upon delivery of the sales, and the remaining 50% upon the completion of the harvest, whether the seeds result in a successful crop, or not. In addition, the Company had a right of first refusal to purchase products resulting from the harvest.

 

Inventory

 

Inventories are stated at the lower of cost or net realizable value. Cost is determined on a standard cost basis that approximates the first-in, first-out (FIFO) method. Appropriate consideration is given to obsolescence, excessive levels, deterioration, and other factors in evaluating net realizable value. Our cannabis products consist of cannabis flower grown in-house, along with produced extracts.

 

8

 

 

ONE WORLD PRODUCTS, INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

 

Stock-Based Compensation

 

The Company accounts for equity instruments issued to employees and non-employees in accordance with the provisions of ASC 718 Stock Compensation (ASC 718). All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date of the fair value of the equity instrument issued is the earlier of the date on which the counterparty’s performance is complete or the date at which a commitment for performance by the counterparty to earn the equity instruments is reached because of sufficiently large disincentives for nonperformance.

 

Basic and Diluted Loss Per Share

 

The basic net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding. Diluted net loss per common share is computed by dividing the net loss adjusted on an “as if converted” basis, by the weighted average number of common shares outstanding plus potential dilutive securities. For the periods presented, potential dilutive securities had an anti-dilutive effect and were not included in the calculation of diluted net loss per common share.

 

Recent Accounting Pronouncements

 

From time to time, new accounting pronouncements are issued by the FASB that are adopted by the Company as of the specified effective date. If not discussed, management believes that the impact of recently issued standards, which are not yet effective, will not have a material impact on the Company’s financial statements upon adoption.

 

In December 2023, the FASB issued Accounting Standards Update (“ASU”) 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures,” which requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. The guidance is effective for the Company’s fiscal years beginning after December 15, 2024, with early adoption permitted. The Company does not expect the adoption of this standard to have any material impact on its financial statements.

 

There are no other recently issued accounting pronouncements that the Company has yet to adopt that are expected to have a material effect on its financial position, results of operations, or cash flows.

 

Note 2 –Going Concern

 

As shown in the accompanying condensed consolidated financial statements as of March 31, 2024, our balance of cash on hand was $40,648, and we had negative working capital of $1,871,931 and an accumulated deficit of $28,630,708. We are too early in our development stage to project future revenue levels, and may not be able to generate sufficient funds to sustain our operations for the next twelve months. Accordingly, we may need to raise additional cash to fund our operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern.

 

In the event sales do not materialize at the expected rates, management would seek additional financing and would attempt to conserve cash by further reducing expenses. There can be no assurance that we will be successful in achieving these objectives; therefore, without sufficient financing it would be unlikely for the Company to continue as a going concern.

 

The condensed consolidated financial statements do not include any adjustments that might result from the outcome of any uncertainty as to the Company’s ability to continue as a going concern. The condensed consolidated financial statements also do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern. Our ability to scale production and distribution capabilities and further increase the value of our brands, is largely dependent on our success in raising additional capital.

 

9

 

 

ONE WORLD PRODUCTS, INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

 

Note 3 – Deconsolidation of Foreign Subsidiaries

 

On December 22, 2023, our wholly-owned subsidiary, One World Products, S.A.S., a Colombian Simplified Shares Company, filed for protection under Colombian Law 1116 of 2006, which is the primary legislation governing business insolvency proceedings (restructuring and liquidation) (“Reorganization Proceedings”) in Colombia. The Reorganization Proceeds are similar to Chapter 11 of the Bankruptcy Code in the United States, whereby the Company intends to restructure its debts and continue to operate. The plan of reorganization and assessment of valid claims has not yet been determined, or approved by the Court and creditors, as necessary. OWP SAS has currently identified approximately 23 creditors, consisting of approximately $1.2 million of financial obligations, collectively. In accordance with ASC 810-10-15, the Company has deconsolidated its foreign subsidiaries until it emerges from the Reorganization Proceedings to include the petitioning entity, OWP SAS. Given the lack of independently identifiable operations, the Company has also deconsolidated its non-operating shell entities, Agrobase, S.A.S. and Hope Colombia, S.A.S (collectively, the “Foreign Subsidiaries”). The deconsolidation resulted in a loss on deconsolidation of foreign subsidiaries in the amount of $97,672 and $1,564,823 for the three months ended March 31, 2024 and the year ended December 31, 2023, respectively. A summary of the deconsolidated condensed combined balance sheets and statement of operations and comprehensive loss of the Foreign Subsidiaries is as follows:

 

FOREIGN SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

 

   March 31,   December 31, 
   2024   2023 
         
Assets          
           
Current assets:          
Cash  $3,804   $1,660 
Inventory   45,616    45,791 
Other current assets   48,231    2,687 
Total current assets   97,651    50,138 
           
Other assets   225,348    226,542 
Fixed assets, net   2,333,021    2,346,281 
           
Total Assets  $2,656,020   $2,622,961 
           
Liabilities and Stockholders’ Equity (Deficit)          
           
Current liabilities:          
Accounts payable  $396,773   $392,403 
Accrued expenses   472,606    482,587 
Notes payable   182,183    183,148 
Intercompany liabilities owed to OWP Ventures, Inc.   7,528,031    7,348,034 
Total current liabilities   8,579,593    8,406,172 
           
Stockholders’ Equity (Deficit):          
Accumulated other comprehensive income   5,463    - 
Accumulated (deficit)   (5,929,036)   (5,783,211)
Total Stockholders’ Equity (Deficit)   (5,923,573)   (5,783,211)
           
Total Liabilities and Stockholders’ Equity (Deficit)  $2,656,020   $2,622,961 

 

10

 

 

ONE WORLD PRODUCTS, INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

 

FOREIGN SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS

 

   For the Three 
   Months Ended 
   March 31, 
   2024 
     
Operating expenses:     
General and administrative  $77,866 
Professional fees   14,966 
Depreciation expense   13,260 
Total operating expenses   106,092 
      
Operating loss   (106,092)
      
Other income (expense):     
Interest expense   (39,733)
Total other expense   (39,733)
      
Net loss  $(145,825)
Other comprehensive loss:     
Gain on foreign currency translation  $5,463 
      
Net loss  $(140,362)

 

FOREIGN SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

 

   For the Three 
   Months Ended 
   March 31, 
   2024 
Cash flows from operating activities     
Net loss  $(145,825)
Adjustments to reconcile net loss to net cash used in operating activities:     
Depreciation and amortization expense   13,260 
Decrease (increase) in assets:     
Inventory   175 
Other current assets   (45,544)
Other assets   1,194 
Increase (decrease) in liabilities:     
Accounts payable   4,370 
Accrued expenses   (10,131)
Accrued interest on interCompany loans   39,997 
Net cash used in operating activities   (142,504)
      
Cash flows from financing activities     
Proceeds received from interCompany loan   140,000 
Net cash provided by financing activities   140,000 
      
Effect of exchange rate changes on cash   4,648 
      
Net increase (decrease) in cash   2,144 
Cash - beginning   1,660 
Cash - ending  $3,804 
      
Supplemental disclosures:     
Interest paid  $- 
Income taxes paid  $- 

 

Note 4 – Related Party Transactions

 

Common Stock Issued as Consideration for Related Party Debt Modifications

 

On March 15, 2024, the Company, through its wholly-owned subsidiary, OWP Ventures, Inc., agreed to issue shares of common stock to officers and directors in consideration for extending the maturity dates and terms of previously received debt financing, as listed below. The aggregate fair value of the common stock was $724,086, based on the closing price of the Company’s common stock on the date of grant, which was recognized as a loss on early extinguishment of debt. The previously issued promissory notes were cancelled in exchange for promissory notes with a maturity date of March 1, 2027, bearing interest at 10% per annum, with the exception of the promissory note issued to Dr. John McCabe, which carries an interest rate of 7% per annum.

 

      Aggregate         
Name  Position  Debts Extended   Shares   Fair Value 
Isiah L. Thomas, III  Chairman and CEO  $27,467    138,000   $9,108 
Dr. Kenneth Perego, II  Vice Chairman   337,000    1,685,000    111,210 
Joerg Sommer  President   26,116    131,000    8,646 
Dr. John McCabe  >5% Shareholder   1,803,398    9,017,000    595,122 
      $2,193,981    10,971,000   $724,086 

 

11
 

 

Common Stock Issued for Services, Related Parties

 

On June 15, 2023, the Company issued 1,500,000 shares of common stock to the Company’s President, Joerg Sommer, for services provided. The aggregate fair value of the common stock was $89,850, based on the closing price of the Company’s common stock on the date of grant. The shares were expensed upon issuance.

 

On March 15, 2024, the Company issued shares of common stock to officers and directors for services provided, as listed below. The aggregate fair value of the common stock was $429,000, based on the closing price of the Company’s common stock on the date of grant. The shares were expensed upon issuance.

 

Name  Position  Shares   Fair Value 
Isiah L. Thomas, III  Chairman and CEO   2,000,000   $132,000 
Dr. Kenneth Perego, II  Vice Chairman   2,000,000    132,000 
Terry Buffalo  Director   2,000,000    132,000 
Joerg Sommer  President   500,000    33,000 
       6,500,000   $429,000 

 

Note 5 – Fair Value of Financial Instruments

 

Under FASB ASC 820-10-5, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (an exit price). The standard outlines a valuation framework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the related disclosures. Under GAAP, certain assets and liabilities must be measured at fair value, and FASB ASC 820-10-50 details the disclosures that are required for items measured at fair value.

 

The Company has certain financial instruments that must be measured under the new fair value standard. The Company’s financial assets and liabilities are measured using inputs from the three levels of the fair value hierarchy. The three levels are as follows:

 

Level 1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.

 

Level 2 - Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).

 

Level 3 - Unobservable inputs that reflect our assumptions about the assumptions that market participants would use in pricing the asset or liability.

 

The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheet as of March 31, 2024 and December 31, 2023, respectively:

  

   Level 1   Level 2   Level 3 
   Fair Value Measurements at March 31, 2024 
   Level 1   Level 2   Level 3 
Assets            
Cash  $40,648   $-   $- 
Total assets   40,648    -    - 
Liabilities               
Notes payable, related parties, net of $9,729 of debt discounts   -    2,441,252    - 
Notes payable, net of $126,670 of debt discounts   -    268,330    - 
Total liabilities   -    (2,709,582)   - 
Fair Value, Net Asset (Liability)  $40,648   $(2,709,582)  $- 

 

   Level 1   Level 2   Level 3 
   Fair Value Measurements at December 31, 2023 
   Level 1   Level 2   Level 3 
Assets            
Cash  $726   $-   $- 
Total assets   726    -    - 
Liabilities               
                
Convertible notes payable, related party   -    750,000    - 
Notes payable, related parties   -    1,146,500    - 
Notes payable, net of $24,136 of debt discounts   -    310,864    - 
Total liabilities   -    (2,207,364)   - 
Fair Value, Net Asset (Liability)  $726   $(2,207,364)  $- 

 

12

 

 

ONE WORLD PRODUCTS, INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

 

There were no transfers of financial assets or liabilities between Level 1, Level 2 and Level 3 inputs for the three months ended March 31, 2024 or the year ended December 31, 2023.

 

Note 6 – Inventory

 

Inventories are stated at the lower of cost or net realizable value. Cost is determined on a standard cost basis that approximates the first-in, first-out (FIFO) method. Appropriate consideration is given to obsolescence, excessive levels, deterioration, and other factors in evaluating net realizable value. Our CBD products consist entirely of finished goods. Inventory was $26,257 at March 31, 2024.

 

Note 7 – Security Deposits

 

Security deposits consisted of refundable deposits on equipment purchases in the amount of $85,000 as of March 31, 2024 and December 31, 2023.

 

Note 8 – Accrued Expenses

 

Accrued expenses consisted of the following at March 31, 2024 and December 31, 2023, respectively:

 

   March 31,   December 31, 
   2024   2023 
Accrued compensation  $759,917   $665,417 
Accrued interest   111,919    273,951 
Accrued expenses  $871,836   $939,368 

 

Note 9 – Convertible Note Payable, Related Party

 

Convertible note payable, related party consists of the following at March 31, 2024 and December 31, 2023, respectively:

 

    March 31,     December 31,  
    2024     2023  
On September 27, 2022                    -        750,000   
On September 27, 2022, the Company completed the sale of a Convertible Promissory Note in the principal amount of $750,000 (the “Convertible McCabe Note”) to Dr. John McCabe, an affiliate investor. The unsecured note matured on September 16, 2024 (the “Maturity Date”), carried interest at a rate of 8% per annum, and the principal and interest were convertible into shares of the Company’s convertible Series B common stock at a conversion price of $15 per share. On March 15, 2024, the Company, through its wholly-owned subsidiary, OWP Ventures, Inc., exchanged the $750,000 of principal, and $90,740 of accrued interest, along with other debts and interest, for a promissory note with a maturity date of March 1, 2027, bearing interest at 7% per annum. As consideration for condensing these loans and extending the maturity dates, the Company awarded Mr. McCabe 9,017,000 shares of common stock. The aggregate fair value of the common stock was $595,122, based on the closing price of the Company’s common stock on the date of grant.   $                -     $ 750,000  
                 
Total convertible note payable, related party     -       750,000  
Less: current maturities     -       -  
Convertible note payable, related party, long-term portion   $ -     $ 750,000  

 

The Company recorded interest expense pursuant to the stated interest rates on the convertible note, related party in the amount of $15,124 and $14,795 for the three months ended March 31, 2024 and 2023, respectively.

 

13

 

 

ONE WORLD PRODUCTS, INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

 

Note 10 – Notes Payable, Related Parties

 

Notes payable, related parties, consists of the following at March 31, 2024 and December 31, 2023, respectively:

 

   March 31,   December 31, 
   2024   2023 
         
On March 19, 2024, the Company, through its wholly-owned subsidiary, OWP Ventures, Inc., received an advance of $50,000 from Joerg Sommer, our President, pursuant to an unsecured promissory note, maturing on March 1, 2027, that carries a 10% interest rate.  $50,000   $- 
           
On March 15, 2024, the Company, through its wholly-owned subsidiary, OWP Ventures, Inc., issued an unsecured promissory note in the amount of $26,116 to Joerg Sommer, our President, maturing on March 1, 2027, that carries a 10% interest rate. The note was issued in exchange for the cancellation of another promissory note, consisting of $25,000 of principal and $1,116 of accrued interest.   26,116    - 
           
On March 15, 2024, the Company, through its wholly-owned subsidiary, OWP Ventures, Inc., issued an unsecured promissory note in the amount of $1,803,398 to Dr. John McCabe, an affiliate investor, maturing on March 1, 2027, that carries a 7% interest rate. The note was issued in exchange for the cancellation of a $840,740 convertible note, consisting of $750,000 of principal and $90,740 of accrued interest., and other promissory notes in the aggregate amount of $962,658, consisting of a total of $850,000 of principal and $112,658 of accrued interest.   1,803,398    - 
           
On March 15, 2024, the Company, through its wholly-owned subsidiary, OWP Ventures, Inc., issued an unsecured promissory note in the amount of $337,000 to Dr. Kenneth Perego, II, M.D., our Vice Chairman of the Board, maturing on March 1, 2027, that carries a 10% interest rate. The note was issued in exchange for the cancellation of promissory notes in the aggregate amount of $337,000, consisting entirely of principal.   337,000    - 
           
On March 15, 2024, the Company, through its wholly-owned subsidiary, OWP Ventures, Inc., issued an unsecured promissory note in the amount of $27,467 to Isiah L. Thomas, III, our Chairman of the Board and CEO, maturing on March 1, 2027, that carries a 10% interest rate. The note was issued in exchange for the cancellation of another promissory note, consisting of $24,500 of principal and $2,967 of accrued interest.   27,467    - 
           
On March 12, 2024, the Company, through its wholly-owned subsidiary, OWP Ventures, Inc., received an advance of $100,000 from Dr. Kenneth Perego, II, M.D., our Vice Chairman of the Board, pursuant to an unsecured promissory note due on demand that carries a 10% interest rate.   100,000    - 
           
On March 1, 2024, the Company, through its wholly-owned subsidiary, OWP Ventures, Inc., received an advance of $100,000 from Dr. John McCabe, an affiliate investor, pursuant to an unsecured promissory note, maturing on March 1, 2025, that carried an 8% interest rate. The note was cancelled on March 15, 2024, in exchange for the note maturing on March 1, 2027, listed above.   -    - 
           
On February 26, 2024, the Company, through its wholly-owned subsidiary, OWP Ventures, Inc., received an advance of $27,000 from Dr. Kenneth Perego, II, M.D., our Vice Chairman of the Board, pursuant to an unsecured promissory note due on demand that carries a 10% interest rate.   27,000    - 
           
On January 29, 2024, the Company, through its wholly-owned subsidiary, OWP Ventures, Inc., received an advance of $50,000 from Dr. John McCabe, an affiliate investor, pursuant to an unsecured promissory note, maturing on January 29, 2025, that carried an 8% interest rate. The note was cancelled on March 15, 2024, in exchange for the note maturing on March 1, 2027, listed above.   -    - 
           
On January 11, 2024, the Company, through its wholly-owned subsidiary, OWP Ventures, Inc., received an advance of $10,000 from Dr. Kenneth Perego, II, M.D., our Vice Chairman of the Board, pursuant to an unsecured promissory note due on demand that carries a 10% interest rate.   10,000    - 
           
On January 8, 2024, the Company, through its wholly-owned subsidiary, OWP Ventures, Inc., received an advance of $10,000 from Dr. Kenneth Perego, II, M.D., our Vice Chairman of the Board, pursuant to an unsecured promissory note due on demand that carries a 10% interest rate.   10,000    - 
           
On November 28, 2023, the Company, through its wholly-owned subsidiary, OWP Ventures, Inc., received an advance of $60,000 from Dr. Kenneth Perego, II, M.D., our Vice Chairman of the Board, pursuant to an unsecured promissory note due on demand that carries a 10% interest rate.   60,000    60,000 
           
On October 11, 2023, the Company, through its wholly-owned subsidiary, OWP Ventures, Inc., received an advance of $25,000 from the Company’s President, Joerg Sommer, pursuant to an unsecured promissory note due on demand that carries a 10% interest rate. The note was cancelled on March 15, 2024, in exchange for the note maturing on March 1, 2027, listed above.   -    25,000 
           
On September 11, 2023, the Company, through its wholly-owned subsidiary, OWP Ventures, Inc., received an advance of $52,000 from Dr. Kenneth Perego, II, M.D., our Vice Chairman of the Board, pursuant to an unsecured promissory note due on demand that carries a 10% interest rate. The note was cancelled on March 15, 2024, in exchange for the note maturing on March 1, 2027, listed above.   -    52,000 
           
On August 31, 2023, the Company, through its wholly-owned subsidiary, OWP Ventures, Inc., received an advance of $4,000 from Dr. Kenneth Perego, II, M.D., our Vice Chairman of the Board, pursuant to an unsecured promissory note due on demand that carries a 6% interest rate. The note was cancelled on March 15, 2024, in exchange for the note maturing on March 1, 2027, listed above.   -    4,000 
           
On August 14, 2023, the Company, through its wholly-owned subsidiary, OWP Ventures, Inc., received an advance of $6,000 from Dr. Kenneth Perego, II, M.D., our Vice Chairman of the Board, pursuant to an unsecured promissory note due on demand that carries a 6% interest rate. The note was cancelled on March 15, 2024, in exchange for the note maturing on March 1, 2027, listed above.   -    6,000 
           
On August 5, 2022, the Company, through its wholly-owned subsidiary, OWP Ventures, Inc., received an advance of $50,000 from Dr. Kenneth Perego, II, M.D., our Vice Chairman of the Board, pursuant to an unsecured promissory note due on demand that carries a 6% interest rate. The note was cancelled on March 15, 2024, in exchange for the note maturing on March 1, 2027, listed above.   -    50,000 
           
On August 2, 2022, the Company, through its wholly-owned subsidiary, OWP Ventures, Inc., received an advance of $4,500 from Isiah L. Thomas, III, our Chairman of the Board and CEO, pursuant to an unsecured promissory note due on demand that carries a 6% interest rate. The note was cancelled on March 15, 2024, in exchange for the note maturing on March 1, 2027, listed above.   -    4,500 
           
On June 13, 2022, the Company, through its wholly-owned subsidiary, OWP Ventures, Inc., received an advance of $100,000 from Dr. John McCabe, an affiliate investor, pursuant to an unsecured promissory note, maturing on January 1, 2024, that carries an 8% interest rate. The note was cancelled on March 15, 2024, in exchange for the note maturing on March 1, 2027, listed above.   -    100,000 
           
On July 7, 2022, the Company, through its wholly-owned subsidiary, OWP Ventures, Inc., received an advance of $5,000 from Dr. Kenneth Perego, II, M.D., our Vice Chairman of the Board pursuant to an unsecured promissory note due on demand that carries a 6% interest rate. The note was cancelled on March 15, 2024, in exchange for the note maturing on March 1, 2027, listed above.   -    5,000 
           
On June 3, 2022, the Company, through its wholly-owned subsidiary, OWP Ventures, Inc., received an advance of $10,000 from Isiah L. Thomas, III, our Chairman of the Board and CEO, pursuant to an unsecured promissory note due on demand that carries a 6% interest rate. The note was cancelled on March 15, 2024, in exchange for the note maturing on March 1, 2027, listed above.   -    10,000 
           
On May 5, 2022, the Company, through its wholly-owned subsidiary, OWP Ventures, Inc., received an advance of $10,000 from Isiah L. Thomas, III, our Chairman of the Board and CEO, pursuant to an unsecured promissory note due on demand that carries a 6% interest rate. The note was cancelled on March 15, 2024, in exchange for the note maturing on March 1, 2027, listed above.   -    10,000 
           
On May 5, 2022, the Company, through its wholly-owned subsidiary, OWP Ventures, Inc., received an advance of $20,000 from Dr. Kenneth Perego, II, M.D., our Vice Chairman of the Board, pursuant to an unsecured promissory note due on demand that carries a 6% interest rate. The note was cancelled on March 15, 2024, in exchange for the note maturing on March 1, 2027, listed above.   -    20,000 
           
On March 1, 2022, the Company, through its wholly-owned subsidiary, OWP Ventures, Inc., received an advance of $400,000 from Dr. John McCabe, an affiliate investor, pursuant to an unsecured promissory note, maturing on January 1, 2024, that carries an 8% interest rate. The note was cancelled on March 15, 2024, in exchange for the note maturing on March 1, 2027, listed above.   -    400,000 
           
On February 15, 2022, the Company, through its wholly-owned subsidiary, OWP Ventures, Inc., received an advance of $200,000 from Dr. John McCabe, an affiliate investor, pursuant to an unsecured promissory note, maturing on January 1, 2024, that carries an 8% interest rate. The note was cancelled on March 15, 2024, in exchange for the note maturing on March 1, 2027, listed above.   -    200,000 
           
On December 29, 2021, the Company, through its wholly-owned subsidiary, OWP Ventures, Inc., received an advance of $200,000 from Dr. Kenneth Perego, II, M.D., our Vice Chairman of the Board, pursuant to an unsecured promissory note due January 1, 2024 that carries an 8% interest rate. The note was cancelled on March 15, 2024, in exchange for the note maturing on March 1, 2027, listed above.   -    200,000 
           
Total notes payable, related parties   2,450,981    1,146,500 
Less: unamortized debt discounts   9,729    - 
Notes payable, related parties, net of discounts   2,441,252    1,146,500 
Less: current maturities   -    1,146,500 
Notes payable, related parties, long-term portion  $2,441,252   $- 

 

The Company recorded interest expense pursuant to the stated interest rates on the notes payable, related parties, in the amount of $29,686 and $5,467 for the three months ended March 31, 2024 and 2023, respectively, including $110 on the amortization of debt discounts for the three months ended March 31, 2024.

 

On March 15, 2024, the Company, through its wholly-owned subsidiary, OWP Ventures, Inc., agreed to issue shares of common stock to officers and directors in consideration for extending the maturity dates and terms of previously received debt financing, as listed below. The aggregate fair value of the common stock was $724,086, based on the closing price of the Company’s common stock on the date of grant, which was recognized as a loss on early extinguishment of debt. As noted above, the previously issued promissory notes were cancelled in exchange for promissory notes with a maturity date of March 1, 2027, bearing interest at 10% per annum, with the exception of the promissory note issued to Dr. John McCabe, which carries an interest rate of 7% per annum.

 

Schedule of Consideration Related Party Debt 

      Aggregate         
Name  Position  Debts Extended   Shares   Fair Value 
Isiah L. Thomas, III  Chairman and CEO  $27,467    138,000   $9,108 
Dr. Kenneth Perego, II  Vice Chairman   337,000    1,685,000    111,210 
Joerg Sommer  President   26,116    131,000    8,646 
Dr. John McCabe  >5% Shareholder   1,803,398    9,017,000    595,122 
      $2,193,981    10,971,000   $724,086 

 

14

 

 

ONE WORLD PRODUCTS, INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

 

Note 11 – Notes Payable

 

   March 31,   December 31, 
   2024   2023 
On March 4, 2024, the Company completed the sale of a promissory note to the Sanguine Group, LLC (“Sanguine”) in the principal amount of $360,000 for a net purchase price of $300,000 after deduction of a $60,000 Original Issue Discount that is being amortized over the life of the loan, pursuant to a securities purchase agreement between the Company and Sanguine. The Note matures on September 4, 2024, and bears interest at a rate of 15% per annum, calculated based on a 360-day year. The Company also paid $15,000 of legal fees and a commitment fee in the form of 2,500,000 shares of common stock, as noted, below. The proceeds were used to repay the Third AJB Note in the principal amount of $300,000. The promissory note was repaid on April 22, 2024 out of proceeds received from debt financing received by SDT Equities LLC.
 
Pursuant to the Purchase Agreement, the Company paid a commitment fee to Sanguine in the form of 2,500,000 shares of the Company’s common stock (the “Commitment Fee Shares”). The Commitment Fee Shares resulted in a debt discount of $73,454 that is being amortized over the life of the loan.
  $360,000   $- 
           
On August 18, 2023, the Company, through its wholly-owned subsidiary, OWP Ventures, Inc., issued an unsecured promissory note of $35,000 to LDL8 Consulting, LLC for the purchase of equipment from another vendor. The promissory note bears interest at 10% per annum and is due on demand. In the event of default, the interest rate increases to 15% until repayment.   35,000    35,000 
           

On June 23, 2023, the Company completed the sale of a Promissory Note in the principal amount of $300,000 (the “Third AJB Note”) to AJB Capital Investments LLC (“AJB Capital”) for an aggregate purchase price of $276,000, pursuant to a Securities Purchase Agreement between the Company and AJB Capital (the “Purchase Agreement”). The Company received net proceeds of $262,500 after deduction of an original issue discount of $24,000, $7,500 of legal fees and a $6,000 of broker fee, which were amortized as a debt discount over the life of the loan.

 

The Third AJB Note matured on March 23, 2024 (the “Maturity Date”), carried interest at a rate of 12% per annum, and, following an event of default only, was convertible into shares of the Company’s common stock at a conversion price equal to the lesser of the Volume Weighted Average Price (“VWAP”) during (i) the 10-trading day period preceding the issuance date of the note, or (ii) the 10-trading day period preceding date of conversion of the Note. The Note was also subject to covenants, events of defaults, penalties, default interest and other terms and conditions customary in transactions of this nature.

 

Pursuant to the Purchase Agreement, the Company paid a commitment fee to AJB Capital in the amount of $100,000 (the “Commitment Fee”) in the form of 1,666,667 shares of the Company’s common stock (the “Commitment Fee Shares”). During the period commencing on the six-month anniversary of the closing date and ending on the five-year anniversary of the closing date, AJB Capital is entitled to be issued additional shares of common stock or receive a cash payment to the extent AJB Capital’s sale of the Commitment Fee Shares has resulted in net proceeds in an amount less than the Commitment Fee. The Commitment Fee Shares resulted in a debt discount of $42,175 that was amortized over the life of the loan.

 

In connection with the issuance of the Third AJB Note and Commitment Fee Shares, the Company entered into a Registration Rights Agreement with AJB Capital in which the Company agreed to file a registration statement with the SEC within 180 days of June 23, 2023, registering the shares of common stock issuable under the Third AJB Note and Purchase Agreement. The note was repaid on March 14, 2024 out of the proceeds received from the Sanguine Group Note.

   -    300,000 
           
Total notes payable   395,000    335,000 
Less: unamortized debt discounts   126,670    24,136 
Notes payable, net of discounts   268,330    310,864 
Less: current maturities   268,330    310,864 
Notes payable, long-term portion  $-   $- 

 

15

 

 

ONE WORLD PRODUCTS, INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

 

The Company recognized aggregate debt discounts on the notes payable to for the three months ended March 31, 2024, as follows:

 

   March 31,   December 31, 
   2024   2023 
         
Fair value of commitment shares of common stock  $73,454   $42,175 
Original issue discounts   60,000    24,000 
Legal and brokerage fees   15,000    13,500 
Total debt discounts   148,454    79,675 
Amortization of debt discounts   21,784    26,233 
Unamortized debt discounts  $126,670   $53,442 

 

The aggregate debt discounts of $148,454 and $79,675, from the Sanguine and AJB Notes, respectively, are being amortized over the life of the loans using the straight-line method, which approximates the effective interest method. The Company recorded finance expense in the amount of $45,920 and $-0- on the amortization of these discounts for the three months ended March 31, 2024 and 2023, respectively.

 

The convertible note limits the maximum number of shares that can be owned by the note holder as a result of the conversions to common stock to 4.99% of the Company’s issued and outstanding shares.

 

The Company recorded interest expense pursuant to the stated interest rates on the notes payable in the amount of $11,250 and $37,808 for the three months ended March 31, 2024 and 2023, respectively.

 

The Company recognized interest expense for the three months ended March 31, 2024 and 2023, as follows:

 

   March 31,   March 31, 
   2024   2023 
         
Interest on convertible notes, related party  $15,123   $14,795 
Interest on notes payable, related parties   29,576    5,467 
Interest on notes payable   11,250    37,808 
Amortization of debt discounts, related parties   110    - 
Amortization of debt discounts, common stock   23,555    - 
Amortization of debt discounts   22,365    - 
Total interest expense  $101,979   $58,070 

 

Note 12 – Convertible Preferred Stock

 

Preferred Stock

 

The Company has 10,000,000 authorized shares of $0.001 par value “blank check” preferred stock, of which 500,000 shares have been designated Series A Preferred Stock and 600,000 shares have been designated Series B Preferred Stock, as amended on August 2, 2022. The shares of Series A Preferred Stock and Series B Preferred Stock are each currently convertible into one hundred (100) shares of the Company’s common stock. The Series A Preferred Stock accrues dividends at the rate of 6% per annum, payable in cash as and when declared by the Board or upon a liquidation. The shares of Series B Preferred Stock are not entitled to dividends, other than the right to participate in dividends payable to holders of common stock on an as-converted basis. As of March 31, 2024, there were 99,733 and 238,501 shares of Series A Preferred Stock and Series B Preferred Stock, respectively, issued and outstanding. The Series A and B Preferred Stock are presented as mezzanine equity on the balance sheet due because they carry a stated value of $10 and $15 per share, respectively, and a deemed liquidation clause, which entitles the holders thereof to receive proceeds thereof in an amount equal to the stated value per share, plus any accrued and unpaid dividends, before any payment may be made to holders of common stock. Each share of Preferred Stock carries a number of votes equal to the number of shares of common stock into which such Preferred Stock may then be converted. The Preferred Stock generally will vote together with the common stock and not as a separate class.

 

16

 

 

ONE WORLD PRODUCTS, INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

 

The Series A and B Preferred Stock have been classified outside of permanent equity and liabilities. the Series A Preferred Stock embodies conditional obligations that the Company may settle by issuing a variable number of equity shares, and in both the Series A and B Preferred Stock, monetary value of the obligation is based on a fixed monetary amount known at inception.

 

Preferred Stock Dividends

 

The Series A Preferred Stock accrues dividends at the rate of 6% per annum, payable in cash as and when declared by the Board or upon a liquidation. The Company recognized $14,916 and $12,773 for the three months ended March 31, 2024 and 2023, respectively. A total of $211,650 of dividends had accrued as of March 31, 2024.

 

Note 13 – Commitments and Contingencies

 

Equity Line of Credit

 

On September 1, 2022, the Company entered into a Purchase Agreement (the “ELOC Purchase Agreement”) with Tysadco Partners, LLC (“Tysadco”). Pursuant to the ELOC Purchase Agreement, Tysadco has agreed to purchase from the Company, from time to time upon delivery by the Company to Tysadco of “Request Notices,” and subject to the other terms and conditions set forth in the ELOC Purchase Agreement, up to an aggregate of $10,000,000 of the Company’s common stock. The purchase price of the shares of common stock to be purchased under the Purchase Agreement will be equal to 88% of the lowest daily “VWAP” during the period of 10 trading days beginning five trading days preceding the applicable Request. Each purchase under the Purchase Agreement will be in a minimum amount of $25,000 and a maximum amount equal to the lesser of (i) $1,000,000 and (ii) 500% of the average daily trading value of the common stock over the seven trading days preceding the delivery of the applicable Request Notice.

 

In connection with the ELOC Purchase Agreement, the Company entered into a Registration Rights Agreement with Tysadco under which the Company agreed to file a registration statement with the Securities and Exchange Commission covering the shares of common stock issuable under the ELOC Purchase Agreement and conversion of the Commitment Fee Shares (the “Registration Rights Agreement”). There have not been any advances on this arrangement to date.

 

Contingent Compensation

 

On August 22, 2023, the Company entered into an advisor agreement with an individual to provide consulting and business advisory services to the Company. Pursuant to the agreement, the Company has agreed to compensate the consultant a fee of $5,000 per month, which is to be deferred until the Company completes the of sale of its equity securities in a transaction, or related series of transactions, resulting in aggregate gross proceeds to the Company of at least $5,000,000, while the Advisor is providing Services (the “Qualified Offering”). Within 60 days of the closing of a Qualified Offering, the Company shall pay to Advisor a cash bonus of up to $200,000. The advisor shall have no participation in any manner or form with any Qualified Offering.

 

On May 23, 2023, the Company appointed Joerg Sommer to be the Company’s President. In connection with his appointment, the Company entered into an offer letter with Mr. Sommer (the “Offer Letter”) under which he will initially be paid an annual base salary of $60,000, which will increase to $240,000 upon the closing of an offering of the Company’s equity securities that results in gross proceeds to the Company of at least $5,000,000. Mr. Sommer received 1,500,000 shares of the Company’s common stock upon his appointment as President; and is entitled to be issued an additional 1,500,000 shares of the Company’s common stock within 60 days of the closing of a Qualified Offering. Mr. Sommer will also be entitled to a bonus of up $380,000 upon the sale of the Company’s equity securities during the term of his employment, as set forth below;

 

$200,000 upon the Company raising $2 million

$80,000 upon the Company raising an additional $1 million

$60,000 upon the Company raising an additional $1 million

$40,000 upon the Company raising an additional $1 million

 

To date, the Company has not received gross proceeds pursuant to the Qualified Offering terms.

 

17

 

 

ONE WORLD PRODUCTS, INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

 

Note 14 – Changes in Stockholders’ Equity

 

Common Stock

 

The Company is authorized to issue an aggregate of 300,000,000 shares of common stock with a par value of $0.001. As of March 31, 2024, there were 111,092,849 shares of common stock issued and outstanding.

 

Common Stock Issued in Escrow Pursuant to Default Provisions of Debt Financing

 

On March 4, 2024, the Company issue 10,394,610 shares of common stock in escrow pursuant to default provisions on deft financing received from the Sanguine Group. The shares are being cancelled pursuant to the subsequent debt repayment on April 22, 2024.

 

Common Stock Issued as a Commitment Fee

 

On March 19, 2024, the Company paid a commitment fee to Joerg Sommer, the Company’s President, in the form of 250,000 shares of common stock in connection with the issuance of the Second Sommer Note (defined above). The relative fair value of the common stock was $9,839, based on the closing price of the Company’s common stock on the date of grant and the fair value of the debt received. The shares are being amortized as a debt discount over the life of the loan.

 

On March 4, 2024, the Company paid a commitment fee to The Sanguine Group, LLC in the form of 2,500,000 shares of common stock in connection with the issuance of the First Sanguine Note (defined above). The relative fair value of the common stock was $73,454, based on the closing price of the Company’s common stock on the date of grant and the fair value of the debt received. The shares are being amortized as a debt discount over the life of the loan.

 

Common Stock Issued as Consideration for Related Party Debt Modifications

 

On March 15, 2024, the Company, through its wholly-owned subsidiary, OWP Ventures, Inc., agreed to issue shares of common stock to officers and directors in consideration for extending the maturity dates and terms of previously received debt financing, as listed below. The aggregate fair value of the common stock was $724,086, based on the closing price of the Company’s common stock on the date of grant, which was recognized as a loss on early extinguishment of debt. The previously issued promissory notes were cancelled in exchange for promissory notes with a maturity date of March 1, 2027, bearing interest at 10% per annum, with the exception of the promissory note issued to Dr. John McCabe, which carries an interest rate of 7% per annum.

 

      Aggregate         
Name  Position  Debts Extended   Shares   Fair Value 
Isiah L. Thomas, III  Chairman and CEO  $27,467    138,000   $9,108 
Dr. Kenneth Perego, II  Vice Chairman   337,000    1,685,000    111,210 
Joerg Sommer  President   26,116    131,000    8,646 
Dr. John McCabe  >5% Shareholder   1,803,398    9,017,000    595,122 
      $2,193,981    10,971,000   $724,086 

 

Common Stock Issued for Services, Related Parties

 

On June 15, 2023, the Company issued 1,500,000 shares of common stock to the Company’s President, Joerg Sommer, for services provided. The aggregate fair value of the common stock was $89,850, based on the closing price of the Company’s common stock on the date of grant. The shares were expensed upon issuance.

 

On March 15, 2024, the Company issued shares of common stock to officers and directors for services provided, as listed below. The aggregate fair value of the common stock was $429,000, based on the closing price of the Company’s common stock on the date of grant. The shares were expensed upon issuance.

 

Name  Position  Shares   Fair Value 
Isiah L. Thomas, III  Chairman and CEO   2,000,000   $132,000 
Dr. Kenneth Perego, II  Vice Chairman   2,000,000    132,000 
Terry Buffalo  Director   2,000,000    132,000 
Joerg Sommer  President   500,000    33,000 
       6,500,000   $429,000 

 

18

 

 

ONE WORLD PRODUCTS, INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

 

Common Stock Issued for Services

 

On March 15, 2024, the Company issued an aggregate 500,000 shares of common stock to two consultants for services provided. The aggregate fair value of the common stock was $33,000, based on the closing price of the Company’s common stock on the date of grant. The shares were expensed upon issuance.

 

On February 9, 2024, the Company issued 149,621 shares of common stock to ClearThink Capital Partners, LLC, for services provided. The fair value of the common stock was $5,386, based on the closing price of the Company’s common stock on the date of grant.

 

Common Stock Subscriptions Payable Issued for Services

 

On March 31, 2024, the Company awarded 381,680 shares of common stock to ClearThink Capital Partners, LLC, for services provided. The fair value of the common stock was $24,695, based on the closing price of the Company’s common stock on the date of grant. The shares were subsequently issued on May 10, 2024.

 

Amortization of Stock-Based Compensation

 

A total of $3,852 and $38,130 of stock-based compensation expense was recognized from the amortization of options to purchase common stock over their vesting period during the three months ended March 31, 2024 and 2023, respectively.

 

Note 15 – Common Stock Options

 

Stock Incentive Plan

 

On February 12, 2020, the Company’s stockholders approved our 2019 Stock Incentive Plan (the “2019 Plan”), which had been adopted by the Company’s Board of Directors (the “Board”) as of December 10, 2019. The 2019 Plan provides for the issuance of up to 10,000,000 shares of common stock to the Company and its subsidiaries’ employees, officers, directors, consultants and advisors, stock options (non-statutory and incentive), restricted stock awards, stock appreciation rights (“SARs”), restricted stock units (“RSUs”) and other performance stock awards. Options granted under the 2019 Plan may either be intended to qualify as incentive stock options under the Internal Revenue Code of 1986, or may be non-qualified options, and are exercisable over periods not exceeding ten years from date of grant. Unless sooner terminated in accordance with its terms, the Stock Plan will terminate on December 10, 2029.

 

Outstanding Options

 

Options to purchase an aggregate total of 10,892,000 shares of common stock at a weighted average strike price of $0.14, exercisable over a weighted average life of 6.99 years were outstanding as of March 31, 2024.

 

The Company recognized a total of $3,852, and $38,130 of compensation expense during the three months ended March 31, 2024 and 2023, respectively, related to common stock options issued in the prior year to officers, directors, and employees that are being amortized over the implied service term, or vesting period, of the options. The remaining unamortized balance of these options is $25,686 as of March 31, 2024.

 

Note 16 – Warrants

 

Outstanding Warrants

 

Warrants to purchase an aggregate total of 14,011,650 shares of common stock at a weighted average strike price of $0.29, exercisable over a weighted average life of 1.66 years were outstanding as of March 31, 2024.

 

Note 17 – Income Taxes

 

The Company accounts for income taxes under FASB ASC 740-10, which requires use of the liability method. FASB ASC 740-10-25 provides that deferred tax assets and liabilities are recorded based on the differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes, referred to as temporary differences.

 

19

 

 

ONE WORLD PRODUCTS, INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

 

For the three months ended March 31, 2024, and the year ended December 31, 2023, the Company incurred a net operating loss and, accordingly, no provision for income taxes has been recorded. In addition, no benefit for income taxes has been recorded due to the uncertainty of the realization of any tax assets. At March 31, 2024, the Company had approximately $10,507,000 of federal net operating losses. The net operating loss carry forwards, if not utilized, will begin to expire in 2025.

 

Based on the available objective evidence, including the Company’s history of its loss, management believes it is more likely than not that the net deferred tax assets will not be fully realizable. Accordingly, the Company provided for a full valuation allowance against its net deferred tax assets at March 31, 2024 and December 31, 2023, respectively.

 

In accordance with FASB ASC 740, the Company has evaluated its tax positions and determined there are no uncertain tax positions.

 

Note 18 – Subsequent Events

 

The Company evaluates events that have occurred after the balance sheet date through the date these financial statements were issued.

 

SDT and AJB Debt Financings

 

On April 19, 2024, the “Company completed the sale of a 12% promissory note to each of (a) SDT Equities LLC, a Delaware limited liability company (“SDT”) in the principal amount of $1,300,000 and for a purchase price of $1,196,000, and (b) AJB Capital Investments LLC, a Delaware limited liability company (“AJB”, and together with SDT, the “Investors”) in the principal amount of $300,000 for a purchase price of $276,000 (collectively, the “Notes”) pursuant to Securities Purchase Agreements between the Company and the Investors, respectively (the “Purchase Agreements”).

 

The Notes mature on January 19, 2025 (the “Maturity Date”) and bear interest at a rate of 12% per annum. Subject to certain adjustments and following an event of default only, the Notes are convertible into shares of the Company’s common stock at a conversion price equal to the lowest closing price (i) during the previous ten Trading Day (as defined in the Notes) period ending on the date of issuance of the Note, or (ii) during the previous ten Trading Day period ending on the Conversion Date (as defined in the Notes), whichever is lower. The Notes are also subject to covenants, events of default, penalties, default interest, and other terms and conditions customary in transactions of this nature.

 

Pursuant to the Purchase Agreement with SDT, SDT received a pre-funded warrant to purchase 8,666,667 shares of the Company’s common stock (the “Warrant”). The Warrant includes a make-whole provision, whereby, if SDT is unable to sell the Warrant Shares (as defined in the Warrant) for net proceeds equal to at least $520,000 (the “Make-Whole Amount”) within a certain timeframe, then the Company shall either (i) pay SDT in cash the difference between the Make-Whole Amount and the net proceeds that SDT actually received from the sale of the Warrant Shares or (ii) cause the issuance of additional pre-funded warrants to SDT for shares of common stock the sale of which would ultimately satisfy the Make-Whole Amount.

 

Pursuant to the Purchase Agreement with AJB, the Company paid a $120,000 commitment fee (the “Commitment Fee”) to AJB in form of 2,000,000 shares of the Company’s common stock (the “Commitment Fee Shares”). The Purchase Agreement with AJB includes a make-whole provision, whereby, if AJB is unable to sell the Commitment Fee Shares for net proceeds equal to at least the Commitment Fee, the Company shall cause the issuance of additional shares of common stock to AJB the sale of which would ultimately generate total net funds equal to the Commitment Fee. Moreover, the Company has an obligation to include the Commitment Fee Shares in a registration statement filed by the Company within ninety days after the effective date of the Purchase Agreement with AJB. A portion of the proceeds were used to repay the $360,000 Sanguine Group, LLC, and $257,446 of debts owed to the Company’s Vice Chairman, Dr. Kenneth Perego, II. The repayments consisted of aggregate principal of $207,000 and aggregate interest of $50,446.

 

Common Stock Issued as a Promissory Note Commitment

 

On April 19, 2024, the Company paid a commitment fee to AJB Capital in the form of 2,000,000 shares of common stock in connection with the issuance of the Fourth AJB Note (defined above). The relative fair value of the common stock was $41,417, based on the closing price of the Company’s common stock on the date of grant and the fair value of the debt received. The shares are being amortized as a debt discount over the life of the loan.

 

Common Stock Issued for Services, Consultants

 

On May 10, 2024, the Company issued 1,250,000 shares of common stock in consideration of consulting services. The fair value of the shares was $76,250, based on the closing price of the Company’s common stock on the date of grant.

 

On May 10, 2024, the Company issued 381,680 shares of common stock to ClearThink Capital Partners, LLC, for services provided. The fair value of the common stock was $24,695, based on the closing price of the Company’s common stock on the date of grant.

 

20

 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The information contained in this Form 10-Q is intended to update the information contained in our Annual Report on Form 10-K for the year ended December 31, 2023 and presumes that readers have access to, and will have read, the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and other information contained in such Form 10-K. The following discussion and analysis also should be read together with our financial statements and the notes to the financial statements included elsewhere in this Form 10-Q.

 

The following discussion contains certain statements that may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements appear in a number of places in this Report, including, without limitation, “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” These statements are not guarantees of future performance and involve risks, uncertainties and requirements that are difficult to predict or are beyond our control. Forward-looking statements speak only as of the date of this quarterly report. You should not put undue reliance on any forward-looking statements. We strongly encourage investors to carefully read the factors described in the Form 10-K in the section entitled “Risk Factors” for a description of certain risks that could, among other things, cause actual results to differ from these forward-looking statements. We assume no responsibility to update the forward-looking statements contained in this quarterly report on Form 10-Q. The following should also be read in conjunction with the unaudited Financial Statements and notes thereto that appear elsewhere in this report.

 

Overview

 

We plan to be a producer of and/or source raw and processed cannabis and hemp plant ingredients for both medical and industrial uses across the globe. The Company is a holding company and conducts its business in Colombia through OWP SAS, its wholly-owned subsidiary. OWP SAS has received licenses from the Colombian government to cultivate, produce and distribute the raw ingredients of the cannabis and hemp plant for medicinal, scientific and industrial purposes in the town of Esmeralda-Popayán, Cauca, Colombia.

 

We have acquired another Colombian subsidiary with the intent to operate within the INTEXZONA free trade zone in Cota, Colombia, near Bogotá, which has all requisite licenses for the cultivation, production, distribution and export of cannabis and hemp infused products, and will serve as the Company’s primary base of operations in the Colombian market. Establishing operations within the free trade zone provides favorable import/export commercial terms and taxation, and will improve logistics and the overall operating efficiencies for the Company due to the close proximity of El Dorado International Airport and the commercial, economic and cultural center of the city of Bogotá itself.

 

OWP SAS owns approximately 30 acres and has a covered greenhouse built specifically to cultivate high-grade cannabis and hemp. In addition, we entered into agreements with a local farming co-operative, under which they will cultivate cannabis on up to approximately 140 acres of land using our seeds and propagation techniques, and sell their harvested products to us on an exclusive basis. We planted our first crop of cannabis in 2018, which we harvested in the first quarter of 2019 for the purpose of further research and development activities and quality control testing of the cannabis we have produced.

 

We have generated revenues since the second quarter of 2020. Between August 2021 and March 2022, we made payments of approximately $1,400,000 for the purchase of a state-of-the-art distillation machine that cleared customs and is currently located in a warehouse near Bogotá. We intend to build out an extraction and production facility in the INTEXZONA free trade zone in Cota, Colombia free trade zone near Bogotá and in close proximity to El Dorado International Airport in Bogotá after we execute a lease for this location. Once the extraction equipment is placed in service, we will be one of the few companies in Colombia to both hold licenses and possess the capability to extract high-quality CBD and THC oils.

 

Due to challenging economic conditions and under prior management, OWP SAS experienced significant operational and managerial challenges in 2022 and 2023, resulting its accumulation of financial obligations of approximately $1.2 million, which are substantially past due. Without adequate resources and in an effort to forestall the imposition of interest, late charges, fines and any Court-mandated order(s) to cease operations, OWP SAS filed for protection under Colombian Law 1116 of 2006, which is the primary legislation governing business insolvency proceedings (restructuring and liquidation) (“Reorganization Proceedings”) in Colombia on December 22, 2023. During the Reorganization Proceeding, management intends to satisfy OWP SAS’s continuing financial obligations through the negotiation and/or settlement with creditors and the Colombian governmental authorities. Subject to Court approval, the Company intends to continue normal operations, which consists of providing cannabinoids in bulk for the domestic and international markets, including the raw material for our brands and affiliate companies. At this time, the Company cannot predict the length of time of the Reorganization Proceeding. The Company has deconsolidated its foreign subsidiaries until it emerges from the Reorganization Proceedings to include the petitioning entity, OWP SAS, as well as the Company’s non-operating shell entities, Agrobase, S.A.S. and Hope Colombia, S.A.S., given the lack of independently identifiable operations. The deconsolidation resulted in a loss on deconsolidation of foreign subsidiaries in the amount of $97,672 and $1,564,823 for the three months ended March 31, 2024 and the year ended December 31, 2023, respectively.

 

We expect the sale of products in 2024, including CBD flower and distillate oil. Our product pipeline may include premium coffee certified by the Colombian National Coffee Federation infused with CBD, teas infused with CBD and a series of wellness products, including sports CBD energy drinks for optimum performance, CBD facial and body creams for anti-inflammatory and anti-aging use and white label commercial agreements with partners in Europe, USA, and Latin America. We recently entered into strategic partnerships with Smokiez Edibles in Colombia and Stephen Marley’s Kx Family Care. There can be no assurances that these strategic partnerships will generate revenues or be profitable for the Company.

 

21

 

 

Results of Operations for the Three Months Ended March 31, 2024 and 2023:

 

The following table summarizes selected items from the statement of operations for the three months ended March 31, 2024 and 2023.

 

   Three Months Ended March 31,   Increase / 
   2024   2023   (Decrease) 
Revenues  $282   $2,101   $(1,819)
Cost of goods sold   49    967    (918)
Gross profit   233    1,134    (901)
                
Operating expenses:               
General and administrative   198,847    347,297    (148,450)
Professional fees   578,671    103,848    474,823 
Depreciation expense   -    7,857    (7,857)
Total operating expenses:   777,518    459,002    318,516 
                
Operating loss   (777,285)   (457,868)   (319,417)
                
Total other expense   (923,737)   (58,070)   (865,667)
                
Net loss  $(1,701,022)  $(515,938)  $(1,185,084)

 

Revenues

 

Revenues during the three months ended March 31, 2024 were $282, compared to $2,101 during the three months ended March 31, 2023, a decrease of $1,819, or 87%. Revenues during the current period were generated by sales of our CBD product, while revenues from the comparative period were attributable to sales of cannabis seeds by OWP SAS.

 

Cost of Goods Sold

 

Cost of goods sold for the three months ended March 31, 2024 were $49, compared to $967 for the three months ended March 31, 2023, a decrease of $918, or 95%. Cost of goods sold consists primarily of labor, agricultural raw materials, depreciation and overhead. Costs of goods sold decreased as we transitioned to the sale of CBD products. Our profit margin during the three months ended March 31, 2024 was 83%, compared to 54% for the three months ended March 31, 2023.

 

General and Administrative Expenses

 

General and administrative expenses for the three months ended March 31, 2024 were $198,847, compared to $347,297 during the three months ended March 31, 2023, a decrease of $148,450, or 43%. The expenses for the current period consisted primarily of compensation expenses, office rent, and travel costs. General and administrative expenses decreased primarily due to decreased salaries and wages and lease expenses in Colombia over the comparative period, as we transitioned to new management. General and administrative expenses included non-cash, stock-based compensation of $33,000 and $29,347 during the each of the three months ended March 31, 2024 and 2023.

 

Professional Fees

 

Professional fees for the three months ended March 31, 2024 were $578,671, compared to $103,848 during the three months ended March 31, 2023, an increase of $474,823, or 457%. Professional fees included non-cash, stock-based compensation of $462,933 and $53,783 during the three months ended March 31, 2024 and 2023, respectively. Professional fees increased primarily due to increased stock-based compensation issued to consultants during the current period.

 

Depreciation Expense

 

Depreciation expense for the three months ended March 31, 2024 was $-0-, compared to $7,857 during the three months ended March 31, 2023, a decrease of $7,857. Depreciation expense decreased due to the deconsolidation of OWP SAS at December 22, 2023.

 

22

 

 

Other Income (Expense)

 

Other expenses, on a net basis, for the three months ended March 31, 2024 were $923,737, compared to other expenses, on a net basis, of $58,070 during the three months ended March 31, 2023, an increase in net expenses of $865,667, or 1,491%. Other expenses consisted of an early extinguishment of debt in the amount of $724,086 related to common stock issued to related parties as commitment shares on debt modifications, a $97,672 loss on deconsolidation of foreign subsidiaries, and $101,979 of interest expense, including $46,030 of stock-based finance costs on the amortization of debt discounts for the three months ended March 31, 2024, compared to $58,070 of interest expense for the three months ended March 31, 2023.

 

Net Loss

 

Net loss for the three months ended March 31, 2024 was $1,701,022, or $0.02 per share, compared to $515,938, or $0.01 per share, during the three months ended March 31, 2023, an increase of $1,185,084, or 230%. The net loss increased primarily due to increased stock-based compensation and the fair value of common stock issued to related parties as commitment shares on debt modifications.

 

Liquidity and Capital Resources

 

The following is a summary of the Company’s cash flows provided by (used in) operating, investing, financing activities and effect of exchange rate changes on cash for the three months ended March 31, 2024 and 2023:

 

   2024   2023 
Operating Activities  $(249,750)  $(561,983)
Investing Activities   -    (5,046)
Financing Activities   332,000    450,000 
Effect of Exchange Rate Changes on Cash   (42,328)   190,722 
Net Decrease in Cash  $39,922   $73,693 

 

Net Cash Used in Operating Activities

 

During the three months ended March 31, 2024, net cash used in operating activities was $249,750, compared to net cash used in operating activities of $561,983 for the three months ended March 31, 2023. The cash used in operating activities was primarily attributable to our net loss.

 

Net Cash Used in Investing Activities

 

During the three months ended March 31, 2024, net cash used in investing activities was $-0-, compared to net cash used in investing activities of $5,046 for the three months ended March 31, 2023. The cash used in investing activities during the prior period consisted entirely of purchases of fixed assets.

 

Net Cash Provided by Financing Activities

 

During the three months ended March 31, 2024, net cash provided by financing activities was $332,000, compared to net cash provided by financing activities of $450,000 for the three months ended March 31, 2023. The current period consisted of $285,000 of proceeds received on debt financing, $347,000 of proceeds received on debt financing received by related parties, as partially offset by $300,000 of debt repayments, compared to $150,000 of proceeds received on the sale of preferred stock and $300,000 from the sale of common stock, during the three months ended March 31, 2023.

 

Ability to Continue as a Going Concern

 

As of March 31, 2024, our balance of cash on hand was $40,648, and we had negative working capital of $1,871,931 and an accumulated deficit of $28,630,708. We are too early in our development stage to project future revenue levels, and may not be able to generate sufficient funds to sustain our operations for the next twelve months. Accordingly, we will need to raise additional cash to fund our operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern.

 

In the event sales do not materialize at the expected rates, management would seek additional financing and would attempt to conserve cash by further reducing expenses. There can be no assurance that we will be successful in achieving these objectives; therefore, without sufficient financing it would be unlikely for the Company to continue as a going concern.

 

23

 

 

The condensed consolidated financial statements do not include any adjustments that might result from the outcome of any uncertainty as to the Company’s ability to continue as a going concern. The condensed consolidated financial statements also do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern. Our ability to scale production and distribution capabilities and further increase the value of our brands, is largely dependent on our success in raising additional capital.

 

Critical Accounting Policies and Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires our management to make assumptions, estimates and judgments that affect the amounts reported, including the notes thereto, and related disclosures of commitments and contingencies, if any. We have identified certain accounting policies that are significant to the preparation of our financial statements. These accounting policies are important for an understanding of our financial condition and results of operations. Critical accounting policies are those that are most important to the presentation of our financial condition and results of operations and require management’s subjective or complex judgment, often as a result of the need to make estimates about the effect of matters that are inherently uncertain and may change in subsequent periods. Certain accounting estimates are particularly sensitive because of their significance to financial statements and because of the possibility that future events affecting the estimate may differ significantly from management’s current judgments.

 

While our significant accounting policies are more fully described in notes to our consolidated financial statements appearing elsewhere in this Form 10-Q, we believe that the following accounting policies are the most critical to aid you in fully understanding and evaluating our reported financial results and affect the more significant judgments and estimates that we used in the preparation of our financial statements.

 

Revenue Recognition

 

The Company recognizes revenue in accordance with ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. The Company’s revenues in the current period consisted of the sale of our CBD rub, and in the prior period revenues consisted entirely of the sale of seeds. The sale of seeds included multi-element arrangements whereby the Company collected 50% of the sale upon delivery of the sales, and the remaining 50% upon the completion of the harvest, whether the seeds result in a successful crop, or not. In addition, the Company had a right of first refusal to purchase products resulting from the harvest.

 

Inventory

 

Inventories are stated at the lower of cost or net realizable value. Cost is determined on a standard cost basis that approximates the first-in, first-out (FIFO) method. Appropriate consideration is given to obsolescence, excessive levels, deterioration, and other factors in evaluating net realizable value. Our cannabis products consist of cannabis flower grown in-house, along with produced extracts and CBD derived products.

 

Stock-Based Compensation

 

The Company accounts for equity instruments issued to employees and non-employees in accordance with the provisions of ASC 718 Stock Compensation (ASC 718). All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date of the fair value of the equity instrument issued is the earlier of the date on which the counterparty’s performance is complete or the date at which a commitment for performance by the counterparty to earn the equity instruments is reached because of sufficiently large disincentives for nonperformance.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide the information required by this Item

 

24

 

 

ITEM 4. CONTROLS AND PROCEDURES

 

Disclosure Controls and Procedures

 

Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2024. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were not effective as of March 31, 2024.

 

Changes in Internal Control over Financial Reporting

 

There have been no significant changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) or in other factors that occurred during the period of our evaluation or subsequent to the date we carried out our evaluation which have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. The design of any system of controls and procedures is based in part upon certain assumptions about the likelihood of future events. There can be no assurance that any system of controls and procedures will succeed in achieving its stated goals under all potential future conditions, regardless of how remote.

 

25

 

 

PART II - OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

Due to challenging economic conditions, OWP SAS filed for protection under Colombian Law 1116 of 2006, which is the primary legislation governing business insolvency proceedings (restructuring and liquidation) (“Reorganization Proceedings”) in Colombia on December 22, 2023. As of March 31, 2024, OWP SAS is involved in a total of 23 separate lawsuits for various civil and labor disputes in the municipal civil courts in Colombia, in the Cities of Bogota, Cali. Funza and Popayán. If the civil courts rule against OWP SAS, we estimate the potential liability from these claims is approximately $310,000. However, this is only an estimate, and our potential liability could be greater.

 

In addition, a complaint was filed in the State of Nevada against One World Products, Inc. on December 8, 2023 by a former employee of OWP SAS. The former employee had filed a similar complaint against OWP SAS, as included in the estimate of potential liabilities noted above.

 

ITEM 1A. RISK FACTORS

 

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide the information required by this Item.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

The following issuances of equity securities by the Company during the three-month period ended March 31, 2024 were exempt from the registration requirements of the Securities Act of 1933, as amended, pursuant to Section 4(a)(2) thereof and Regulation D thereunder:

 

Common Stock Issued in Escrow Pursuant to Default Provisions of Debt Financing

 

On March 4, 2024, the Company issued 10,394,610 shares of common stock, restricted in accordance with Rule 144, in escrow pursuant to default provisions on deft financing received from the Sanguine Group. The shares are being cancelled pursuant to the subsequent debt repayment on April 22, 2024.

 

Common Stock Issued as a Commitment Fee

 

On March 19, 2024, the Company paid a commitment fee to Joerg Sommer, the Company’s President, in the form of 250,000 shares of common stock, restricted in accordance with Rule 144, in connection with the issuance of the Second Sommer Note.

 

On March 4, 2024, the Company paid a commitment fee to The Sanguine Group, LLC in the form of 2,500,000 shares of common stock, restricted in accordance with Rule 144, in connection with the issuance of the First Sanguine Note.

 

Common Stock Issued as Consideration for Related Party Debt Modifications

 

On March 15, 2024, the Company, through its wholly-owned subsidiary, OWP Ventures, Inc., agreed to issue shares of common stock, restricted in accordance with Rule 144, to officers and directors in consideration for extending the maturity dates and terms of previously received debt financing, as listed below. The aggregate fair value of the common stock was $724,086, based on the closing price of the Company’s common stock on the date of grant, which was recognized as a loss on early extinguishment of debt. The previously issued promissory notes were cancelled in exchange for promissory notes with a maturity date of March 1, 2027, bearing interest at 10% per annum, with the exception of the promissory note issued to Dr. John McCabe, which carries an interest rate of 7% per annum.

 

        Aggregate              
Name   Position   Debts Extended     Shares     Fair Value  
Isiah L. Thomas, III   Chairman and CEO   $ 27,467       138,000     $ 9,108  
Dr. Kenneth Perego, II   Vice Chairman     337,000       1,685,000       111,210  
Joerg Sommer   President     26,116       131,000       8,646  
Dr. John McCabe   >5% Shareholder     1,803,398       9,017,000       595,122  
        $ 2,193,981       10,971,000     $ 724,086  

 

Common Stock Issued for Services, Related Parties

 

On June 15, 2023, the Company issued 1,500,000 shares of common stock, restricted in accordance with Rule 144, to the Company’s President, Joerg Sommer, for services provided.

 

26

 

 

On March 15, 2024, the Company issued shares of common stock, restricted in accordance with Rule 144, to officers and directors for services provided, as listed below.

 

Name   Position   Shares     Fair Value  
Isiah L. Thomas, III   Chairman and CEO     2,000,000     $ 132,000  
Dr. Kenneth Perego, II   Vice Chairman     2,000,000       132,000  
Terry Buffalo   Director     2,000,000       132,000  
Joerg Sommer   President     500,000       33,000  
          6,500,000     $ 429,000  

 

Common Stock Issued for Services

 

On March 15, 2024, the Company issued an aggregate 500,000 shares of common stock, restricted in accordance with Rule 144, to two consultants for services provided.

 

On February 9, 2024, the Company issued 149,621 shares of common stock, restricted in accordance with Rule 144, to ClearThink Capital Partners, LLC, for services provided.

 

In connection with the above security issuances, we did not pay any underwriting discounts or commissions. None of the sales of securities described or referred to above was registered under the Securities Act. In making the sales without registration under the Securities Act, we relied upon one or more of the exemptions from registration contained in Section 4(2) of the Securities Act, and in Regulation D promulgated under the Securities Act. No general solicitation or advertising was used in connection with the sales.

 

All of these transactions described above were exempt from registration in reliance on Section 4(a)(2) of the Securities Act of 1933, as amended, as a transaction by an issuer not involving a public offering. We did not pay any underwriting discounts or commissions in any of these transactions. The recipients of securities in each of these transactions represented their intention to acquire these securities for investment only and not with a view to offer or sell, in connection with any distribution of the securities, and appropriate legends were affixed to the share certificates and instruments issued in such transactions.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

None.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

ITEM 5. OTHER INFORMATION

 

None

 

27

 

 

ITEM 6. Exhibits

 

Exhibit   Description
2.1   Agreement and Plan of Merger dated February 21, 2019, among the Company, OWP Merger Subsidiary Inc. and OWP Ventures, Inc. (incorporated by reference to Exhibit 2.1 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 25, 2019)
3.1   Articles of Incorporation of the Company (incorporated by reference to Exhibit 3.1 of the Company’s Registration Statement on Form S-1 filed with the Securities and Exchange Commission on November 24, 2014)
3.2   Certificate of Amendment to Articles of Incorporation of the Company (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on January 8, 2019)
3.3   Certificate of Amendment to Articles of Incorporation of the Company (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 25, 2020)
3.4   Certificate of Designation of Series A Preferred Stock of the Company dated June 1, 2020 (incorporated by reference to Exhibit 3.4 of the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on June 26, 2020)
3.5   Bylaws of the Company (incorporated by reference to Exhibit 3.2 of the Company’s Registration Statement on Form S-1 filed with the Securities and Exchange Commission on November 24, 2014)
3.6   Certificate of Designation of Series B Preferred Stock of the Company dated February 2, 2021 (incorporated by reference to Exhibit 3.1 of the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on February 8, 2021)
4.1   Promissory Note of the Company in the Principal Amount of $300,000 issued to AJB Capital Investments LLC, dated June 23, 2023 (incorporated by reference to Exhibit 4.1 of the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on July 5, 2023)
10.1+   2019 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 25, 2020)
10.2+   Form of Stock Option Grant Notice for grants under the 2019 Stock Incentive Plan (incorporated by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 25, 2020)
10.3+   Form of Option Agreement for grants under the 2019 Stock Incentive Plan (incorporated by reference to Exhibit 10.3 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 25, 2020)
10.4+   Letter Agreement between the Company and Isiah L. Thomas, III, dated June 3, 2020 (incorporated by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 9, 2020)
10.5   Securities Purchase Agreement, dated as of June 23, 2023, between the Company and AJB Capital Investments LLC (incorporated by reference to Exhibit 10.5 of the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on July 5, 2023)
10.6   Securities Purchase Agreement, dated as of February 7, 2021, between the Company and ISIAH International LLC (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 8, 2021)
10.7   Registration Rights Agreement, dated June 23, 2023, between the Company and AJB Capital Investments LLC (incorporated by reference to Exhibit 10.7 of the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on July 5, 2023)
10.8   Commercial Lease Agreement dated November 26, 2021, between R&B Inversiones S.A.S. and One World Pharma S.A.S. (incorporated by reference to Exhibit 10.10 of the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 16, 2022)
10.9   Purchase Agreement, dated September 1, 2022, between the Company and Tysadco Partners, LLC (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on September 7, 2022)
10.10   Securities Purchase Agreement, dated September 1, 2022, between the Company and Tysadco Partners, LLC (incorporated by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on September 7, 2022)
10.11   Registration Rights Agreement, dated September 1, 2022, between the Company and Tysadco Partners, LLC (incorporated by reference to Exhibit 10.3 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on September 7, 2022)
10.12   Convertible Promissory Note Purchase Agreement, dated September 16, 2022, between the Company and Dr. John McCabe (incorporated by reference to Exhibit 10.15 of the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission by One World Products, Inc. on November 14, 2022)
10.13   Convertible Note, dated September 16, 2022, between One World Products, Inc. and Dr. John McCabe (incorporated by reference to Exhibit 10.16 of the Form 10-Q filed with the Securities and Exchange Commission by on November 14, 2022)
10.14+   Offer Letter dated April 25, 2003 by and between the Company and Jeorg Sommer (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 23, 2023)
31.1*   Certification of Chief Executive Officer pursuant to Securities Exchange Act of 1934 Rule 13a-14(a) or 15d-14(a)
31.2*   Certification of Chief Financial Officer pursuant to Securities Exchange Act of 1934 Rule 13a-14(a) or 15d-14(a)
32.1*   Certification of Chief Executive Officer pursuant to Securities Exchange Act of 1934 Rule 13a-14(b) or 15d-14(b) and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2*   Certification of Chief Financial Officer pursuant to Securities Exchange Act of 1934 Rule 13a-14(b) or 15d-14(b) and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS*   Inline XBRL Instance Document
101.SCH*   Inline XBRL Schema Document
101.CAL*   Inline XBRL Calculation Linkbase Document
101.DEF*   Inline XBRL Definition Linkbase Document
101.LAB*   Inline XBRL Labels Linkbase Document
101.PRE*   Inline XBRL Presentation Linkbase Document
104*   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

* Filed herewith.

+ Compensatory plan or agreement.

 

28

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Date: June 12, 2024  
   
  One World Products, Inc.
   
  /s/ Isiah L. Thomas III
  Isiah L. Thomas III
  Chief Executive Officer
  (Principal Executive Officer)
   
  /s/ Timothy Woods
  Timothy Woods
  Chief Financial Officer
  (Principal Financial Officer)

 

29